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ABSTRACT
NATHANIEL RAY DUDLEY: Understanding the molecular mechanisms of RNA 
interference in Caenorhabditis elegans
(Under the direction of Dr. Robert P. Goldstein, Ph.D.)
    RNA interference (RNAi) is a recently discovered phenomenon in which double-stranded 
RNA (dsRNA) silences endogenous gene expression in a sequence-specific manner. RNAi 
shares a remarkable degree of similarity with silencing phenomena in other organisms, 
suggesting that RNAi is part of an ancient and conserved pathway used to regulate gene 
expression, to eliminate defective RNAs and to defend against viral infections and 
transposons. RNAi has also been implicated in developmental processes, suggesting that 
RNAi may play a broader role in regulating normal gene expression.  Since its discovery, the 
use of RNAi has become widely employed in many organisms to specifically knock down 
gene function.  Although we have learned much about the general mechanisms underlying 
RNAi, a detailed understanding of how RNAi works remains to be elucidated.
    I have developed a candidate screen approach in which I use RNAi to identify genes 
required for RNAi.  I identified a number of potential candidates and in a secondary screen, 
using mutant animals, validated roles for several new genes in RNAi. Interestingly, many of 
these genes encode protein known to function in the nucleus, and some of the genes 
identified are members of the well characterized SynMuv B pathway.  In addition, I have 
further characterized the role of a nuclear RNA helicase, These results suggest clues and 
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provide important tools toward furthering our emerging understanding of nuclear 
mechanisms of RNAi interference in animals
iv
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PREFACE
    When I arrived in Bob Goldstein’s lab on June 5th 2000, Bob and I discussed the option of 
beginning a rotation project aimed at identifying genes required early in C. elegans
development. I had two years experience under my belt as a technician in a C. elegans
genetics lab at UPENN, under the direction of Dr. Meera Sundaram, one of the brightest 
young scientists I knew to date (of course, this is before meeting the young upstart, Bob 
Goldstein).  This experience helped me to hit the ground running and I started right away.  In 
fact, Bob welcomed me on June 5th, and on the 6th, he and the rest of his lab bid me farewell 
as they were traveling to a developmental biology meeting that very day… “See you in 
week….”.  While Bob was away, I jumped right into the project, setting up a pilot 
experiment to determine if such a screen was feasible, at least in my hands.  As the lab 
returned, I had made significant progress towards this end and had data to suggest that 
injecting pools of dsRNA, from a germline enriched data set, could indeed give us the 
expected results when using control dsRNAs.
    All my enthusiasm, however, came to a screeching halt as the second pool of dsRNAs, 
containing a dsRNA targeting a known essential transcript, glp-1, a member of the Notch 
family, resulted in completely viable progeny.  I then injected this dsRNA alone, which 
resulted in dead eggs. I was intrigued, since my first thought was that the pool might contain 
a specific suppressor of glp-1 and had begun to see a graduate project developing.  I then co-
xinjected each member of that pool with dsRNA targeting glp-1 and isolated the dsRNA 
responsible for the effect.  I then asked the simple question, could this dsRNA also suppress 
the lethality of other essential targets?  To make a long story short, yes it could!  The details 
of those experiments is the subject of Chapter IV of this dissertation and was subsequently 
published in the journal PNAS.  These results ultimately led to the development of a screen, 
using RNAi, to identify genes required for RNAi.
    One of the surprising results of this screen, was the identification of genes that encode 
nuclear proteins.  This was surprising since, at the time, RNAi in animal systems was 
believed to be a purely cytoplasmic phenomenon.  Our results suggested, however, that gene 
silencing in animals may involve similar mechanisms observed in related phenomena found 
in plants and fungi. My rotation project quickly turned into a graduate project aimed at 
developing an RNAi-based candidate screen to identify additional players in RNAi.  What 
follows, and is reported in this dissertation, is my journey.
    Chapter I introduces our current understanding of the genes required for RNAi and their 
related biology.  This has been published as a chapter in a book entitled, RNA Interference 
Technology : From Basic Science to Drug Development with a foreword by Andrew Fire 
(Dudley et al 2005). Chapter II introduces the nuclear RNAi phenomenon in animals. This 
was published in Current Opinion in Molecular Therapeutics (Dudley and Goldstein 2003).   
Chapter III presents detailed methods for conducting RNAi experiments in C. elegans.  This 
was published as a chapter in a book entitled RNA Interference in Caenorhabditis elegans, 
Methods in Molecular Biology (Dudley and Goldstein 2005).  Chapter IV describes my 
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results in developing the RNAi co-injection and identifying the nuclear proteins.  This has 
been published in PNAS  (Dudley et al 2002).  Chapter V describes the results of a 
candidate-based RNAi screen aimed at identifying new genes required for RNAi, and also 
further characterizes the role of a nuclear RNA helicase, RHA-1, in RNAi.   I intend to 
submit this to Genetics in the next two months.
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CHAPTER I: GENES REQUIRED FOR RNA INTERFERENCE
INTRODUCTION
    RNA interference (RNAi) is a recently discovered phenomenon in which double-stranded 
RNA (dsRNA) silences endogenous gene expression in a sequence-specific manner (1).  
Since its discovery, the use of RNAi has become widely employed in many organisms to 
specifically knock down gene function.
    RNAi shares a remarkable degree of similarity with silencing phenomena in other 
organisms (2, 3). For instance, RNAi, post-transcriptional gene silencing in plants and 
cosuppression in fungi can all be activated by the presence of aberrant RNAs (4, 5). 
Additionally, plant, worm, and fly cells or extracts undergoing RNA-mediated interference 
all contain small dsRNAs, around 25 nucleotides in length, identical to the sequences present 
in the silenced gene (6, 7, 8, 9).
    The high degree of similarity between these RNA-mediated silencing phenomena supports 
the notion that they were derived from an ancient and conserved pathway used to regulate 
gene expression, presumably to eliminate defective RNAs and to defend against viral 
infections and transposons. (7).  Components of RNAi have also been
2 implicated in developmental processes, suggesting that RNAi may play a broader role in 
regulating gene expression (10, 11, 12).
    Although we have learned much about the general mechanisms underlying RNAi, a 
detailed understanding of how RNAi works remains to be elucidated .  In this chapter we will 
discuss first the biology of RNAi, then the genes required for its function, and we will end 
with a discussion on recent findings that have implicated chromatin silencing in the 
mechanism of RNAi.
THE BIOLOGY OF RNAI
    Both genetic and biochemical analyses have significantly increased our understanding of 
how RNAi works.  The RNAi mechanism involves an early step, in which the dsRNA is 
recognized and is targeted for RNase-dependent digestion, and a late step, which comprises 
the downstream events that lead to the silencing of the target gene.
Two-step Model for RNAi
    Figure 1.1 illustrates a current model by which introduction of dsRNAs into a cell can 
result in degradation of targeted mRNAs.  Introduced dsRNAs are recognized by a dsRNA-
binding protein, RDE-4/R2D2 (13, 14), that facilitates the subsequent dicing of these RNAs 
into small interfering RNAs (siRNAs) 21-25 nucleotides in length, with 2-nucleotide 
overhangs at both 3'-ends.  Dicing is catalyzed by an RNase III enzyme named Dicer (6, 15, 
16, 17).
3    These siRNAs then act as guides in association with a protein complex to target 
homologous transcripts for degradation. This siRNA/protein complex, termed RISC, for 
RNA-Induced Silencing Complex (6) becomes competent to target degradation of 
homologous mRNAs upon the ATP-dependent unwinding of the siRNAs (18). 
siRNAs
    siRNAs are complementary to both the sense and antisense strands of the targeted mRNA 
and have a distinct chemical polarity that is essential for their function (7, 17, 18, 19, 20).  
For instance, efficient siRNA mediated interference requires that the siRNAs contain 2bp 
overhangs at their 3’ ends as well as a 5’ phosphate and, at least in Drosophila, a 3' hydroxyl 
group.  Additionally, the base composition at the 5’ end can influence which siRNA strand 
can initiate RNAi.  It has also been shown that the sequence composition of the antisense 
strand is more important than that of the sense strand, as modifications on the antisense 
strand of the dsRNA trigger preferentially blocks RNAi (21). 
    Long dsRNAs cannot be used for gene silencing in some organisms, including mammals, 
because of the presence of dsRNA defense mechanisms.  In these organisms, the introduction 
of dsRNA leads to the activation of the protein kinase PKR and 2',5'-oligoadenylate 
synthetase.  The activation of these two proteins leads to non-sequence-specific effects 
including the inhibition of translation and the degradation of mRNA (22, 23).
4    However, siRNAs alone can elicit a potent and effective RNAi response.  It has been 
shown that chemically synthesized siRNAs, introduced into a variety of mammalian cell 
lines, could also specifically inhibit endogenous gene expression (24). 
    Moreover, RNAi has been shown to work in model organisms such as mice, Drosophila, 
C. elegans, and zebrafish, thus expanding the potential for its use in understanding gene 
function in a variety of model systems (1, 25, 26, 27, 28).  
Systemic Nature of RNAi
    One interesting aspect of RNAi, which was originally observed in plants, is that the effect 
can spread between tissues, in that gene silencing induced in one tissue can result in gene 
silencing in other tissues (1, 29, 30). This suggests the existence of a mechanism to uptake 
and transport a silencing signal between cells. 
Amplification of the RNAi response and transitive RNAi
    Another intriguing aspect of RNAi is that the effect is surprisingly robust.  Concentrations 
as low as a few molecules of dsRNA per cell can elicit a strong and persistent response (1), 
suggesting that an amplification step may occur within the RNAi pathway. 
    In some organisms, it is likely that the amplification mechanism involves RISC acting 
catalytically (31) as amplification could be effected by multiple turnover of RISC (32, 33).  
5In other organisms, the activity of RNA-dependent RNA polymerases (RDRPs) have been 
implicated in the amplification mechanism (4, 11, 31, 34).  The presence of siRNAs with 
sequences 5' to the initial trigger have been demonstrated in some animals undergoing RNAi 
(Fig 1.2).  These siRNAs, called secondary siRNAs, correspond to sequences just upstream 
of targeted sequence on the same transcript and are produced by de novo RNA synthesis by 
an RDRP (31).  However, transitive RNAi does not appear to occur in cultured Drosophila
cells (19, 35, 36).  
    These observations suggest that in certain organisms, mRNAs are not only targets of the 
RNAi machinery but can also be used to amplify the original signal. One consideration for 
researchers using RNAi as a gene silencing tool is that transitive RNAi may also lead to 
inactivation of mRNA species that were not originally targeted by the initial trigger 
sequence; for example, RNAi of Green Fluorescent Protein (GFP) in a strain bearing a GFP 
fusion transgene can in certain cases result in silencing of the gene to which GFP is fused 
(31, 37).
A link between RNAi and microRNAs
    Although not a product of dsRNA-mediated interference, microRNAs (miRNAs) have also 
been shown to be key components of RNA-based gene regulation in many organisms.  In 
contrast to siRNAs, miRNAs are derived from the processing of endogenously-encoded short 
hairpin RNAs.  However, miRNAs are dependent on Dicer for processing (38) and associate 
with a complex that shares components present in RISC (16), suggesting a mechanistic link 
6between the RNAi and miRNA pathways.  Recent studies suggest that miRNAs play 
important roles in controlling development in both plants and animals (38).  Anti-sense 
binding of miRNAs to target mRNA sequences can silence expression by either inhibiting 
translation (in animals) or directing the target mRNA for degradation (in plants) (38). 
GENES REQUIRED FOR RNAI
    Genes required for RNAi (Table 1.1) have been identified by genetic screens aimed at 
isolating mutants that are defective in RNA-mediated silencing, by using RNAi knockdown 
of components of the RNAi machinery, and by biochemical methods.  Determining how 
these proteins function in RNAi is an ongoing challenge.  Here, we discuss the roles of genes 
with defined functions in RNAi.
Initiators
    The C. elegans genes rde-1 and rde-4 (rde stands for "RNAi deficient") are involved in the 
early step of RNAi.  RDE-4 is a double-stranded RNA binding protein required for efficient 
recognition of the dsRNA trigger and, at least in Drosophila, for helping siRNAs transit from 
Dicer to RISC (13, 14). Consistent with RDE-4 acting early, rde-4 mutant animals do not 
produce siRNAs, and the introduction of siRNAs can bypass the requirement for this gene 
(39).  RDE-4 has also been shown to physically associate with Dicer, RDE-1, and a Dicer-
related helicase called DRH-1/2 (13).
7    The rde-1 gene is a member of a large family (composed of over 20 genes in C. elegans), 
and has homologs in Drosophila, plants, fungi, and mammals (40, 41).  RDE-1 is a member 
of the PPD (PAZ and Piwi domain) family of proteins and can physically associate with 
RDE- 4 (13).  However, unlike rde-4, siRNAs cannot bypass the requirement for rde-1, 
suggesting that rde-1 is required downstream of siRNA production.  Interestingly, secondary 
siRNAs are not produced in rde-1 mutants (39, 42).  
Effectors
    Genes required in the late step of RNAi, after formation of siRNAs, include the C. elegans
genes rde-2 and mut-7. These genes were initially identified in screens for mutant animals 
unable to respond to RNAi and from screens designed to identify components that silence 
DNA transposition in the germline (43).  The fact that transposon silencing depends on 
factors required for RNAi suggests that silencing of transposons and RNAi may share related 
mechanisms.
    The mut-7 gene encodes a putative 3'-to-5' exonuclease sharing homology to the nuclease 
domains of RNase D and a helicase implicated in Werner Syndrome, a human premature 
aging disorder (43, 44).  The rde-2 gene product has not yet been identified.
    Current research supports a scheme in which RDE-1 and RDE-4 are required to generate 
siRNAs, whereas RDE-2 and MUT-7 are required to respond to this signal to silence the 
targeted gene.
8RISC Components
    RISC is an siRNA/protein complex that directs the cleavage of targeted transcripts. There 
have been several RISC factors thus far identified.
    Drosophila Argonaute-2 (AGO2, a homolog of C. elegans RDE-1, Neurospora QDE-2, 
and Arabidopsis AGO1) has been shown to associate with RISC during processing of 
miRNAs (32, 45).
    Other components found to be associated with RISC are two RNA-binding proteins: VIG 
(Vasa intronic gene), and FMR1 (fragile X mental retardation syndrome protein) (46).   VIG 
is encoded within an intron of the the Vasa gene in Drosophila and contains a protein motif 
able to bind RNA (47).  FMR1 is the Drosophila homolog of the mammalian fragile X 
mental retardation protein and encodes an RNA-binding protein that associates with 
translating ribosomes and is presumed to act as a negative regulator of translation (48).
 Drosophila Tudor-SN, a nuclease containing domains in common with Tudor and 
staphylococcal nuclease, also associates with RISC (49), and Dicer has been shown to 
associate with RISC, although Dicer is not required for RISC activity (15).
9RNA-Dependent RNA Polymerases
RDRPs have been implicated in RNAi in C. elegans.  The ego-1 gene encodes an RDRP 
required for RNAi specifically in the germline (11, 31).  The C. elegans genome contains 
three additional  RDRP loci -- rrf-1, rrf-2, and rrf-3.  Mutations in rrf-1 result in an RNAi-
deficient phenotype, however, only somatic cells are RNAi-deficient.  RRF-2  appears to 
have no role in RNAi, whereas mutations in rrf-3 make C. elegans hypersensitive to RNAi 
suggesting that it may act as an antagonist to the RNAi pathway (31, 34).
    Certainly, the existence of an RDRP might explain the remarkable efficiency of dsRNA-
induced silencing if it amplified either the dsRNA prior to cleavage or the siRNAs directly.  
RDRP activity has been reported in Drosophila embryo lysates.  However, no homolog of an 
RDRP has been found in the Drosophila and human genomes (50).  Additonally, siRNAs 
that have been modified at their 3’ ends, which can no longer associate with an RDRP, can 
produce efficient RNAi in human tissue culture systems (51).
NOVEL COMPONENT REQUIRED FOR SYSTEMIC RNAI  
    In C. elegans, a genetic screen was recently developed to identify components required for 
systemic RNAi (52, 53).  Over 200  mutants were identified and placed into 5 
complementation groups: sid-1, sid-2, sid-3, sid-4, and sid-5 (for systemic RNA interference 
deficient). 
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    To date, sid-1 has been cloned.  SID-1 localizes to the cell periphery and encodes a novel 
multi-pass transmembrane protein that is required cell autonomously and enables the passive 
uptake of dsRNA into cells.  Interestingly, dsRNAs of approximately 100bp in length 
function as preferred substrates for sid-1-dependent RNAi over shorter dsRNAs (52, 53). 
ROLES FOR CHROMATIN MODIFYING PROTEINS IN RNAI
    Until recently, most models predicted RNAi to act exclusively at the post-transcriptional 
level to target mRNA stability. However, recent work may have revealed an additional role 
for RNAi, a role in regulating transcription.  Work in fission yeast has revealed that RNAi 
silences transcription of genes via chromatin modifications.  Chromatin modification proteins 
have also been implicated in RNAi in C. elegans, and RNAi machinery components have 
been implicated in transcriptional silencing in Drosophila, suggesting that the mechanisms of 
gene silencing found in fission yeast might be operating in animal cells as well (Figure 1.3).
C. ELEGANS: USING RNAI TO IDENTIFY GENES REQUIRED FOR RNAI
    As discussed above, the molecular components of the RNAi machinery have been 
identified by screening for mutants that are RNAi-deficient, and by isolating proteins that 
interact with the known RNAi machinery.  Recently an additional approach to identify RNAi 
components using RNAi itself was fortuitously developed out of a screen originally intended 
to identify genes required for early development.
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    The screen, conducted in C. elegans, involved pooling together eight dsRNAs at a time, 
co-injecting these into hermaphrodites, and identifying pools containing genes essential for 
development by scoring progeny for embryonic lethality.  For pools that resulted in lethality, 
sub-pooling was performed until the dsRNA responsible for the effect was isolated. 
    One such pool contained a dsRNA corresponding to the essential gene, glp-1 (germ line 
proliferation 1).  GLP-1 is a Notch like molecule and loss of glp-1 function results in a 
maternal-effect lethal phenotype.   Surprisingly, no lethality was observed in the pool that 
included glp-1 dsRNA. However, injecting glp-1 dsRNA alone resulted in a high degree of 
lethality. In an attempt to identify the dsRNA responsible for suppressing glp-1(RNAi), each 
dsRNA in this pool was co-injected with glp-1 dsRNA.  It was found that only one of the 
dsRNAs was able to suppress glp-1 (RNAi), and removing this dsRNA from the pool 
restored glp-1 dsRNA-mediated lethality. 
    Interestingly, suppression was not limited to glp-1(RNAi), as the suppressing dsRNA was 
also able to suppress the lethality associated with other dsRNAs, suggesting that the 
suppressing dsRNA might work by affecting RNAi in general, and not just RNAi of glp-1.  
Consistent with this, known components of the RNAi machinery have been found to behave 
similarly (6, 15, 54, 55).  These results suggested that co-injection of multiple dsRNAs could 
be used as an effective method to identify new genes required for RNAi (55).
    Surprisingly, several genes identified using this method in C. elegans encode proteins 
predicted to associate with chromatin, raising the possibility that RNAi in animal cells may 
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also work at the level of chromatin, as it does in plants (8, 56).  Some of the proteins 
identified form a complex that includes a protein homologous to a Drosophila Polycomb 
group protein, which in flies functions to repress gene expression through the chromatin 
modification (57, 58), raising the possibility that repression of transcription by chromatin 
modifying proteins might play a role in RNAi-dependent gene silencing.  
DROSOPHILA: A PIECE OF THE RNAI MACHINERY REQUIRED FOR 
TRANSGENE-MEDIATED TRANSCRIPTIONAL SILENCING
    Recent experiments have shown that polycomb-dependent transcriptional gene silencing is 
disrupted in an RNAi-defective background in Drosophila. (59). In mutants defective for 
piwi, a homolog of the C. elegans RNAi component RDE-1, transcriptional gene silencing 
was impaired alongside with posttranscriptional gene silencing.  Transcription from an 
inserted transgene was monitored in both normal and piwi mutant flies.  In normal flies, 
transcriptional gene silencing was induced by high copy numbers of the inserted transgene, 
while in the piwi mutants transcription was unaffected (59).  These results show that an 
RNAi component is required for at least one aspect of transcriptional silencing.
FISSION YEAST: SILENCING OF CENTROMERIC DNA AND THE MAT LOCUS
    Recent work In the fission yeast Schizosaccharomyces pombe implicates RNAi in both the 
initiation and the maintenance of centromeric silencing (60).  Centromeric DNA is flanked 
on either side by repetitive sequences.  It has recently been shown that a DNA fragment 
normally present within the centromere can be inserted into a transcriptionally active region 
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of chromatin elsewhere and induce chromatin remodeling at the new site.  Modifications 
such as the methylation of lysine 9 of histone H3 subsequently leads to gene silencing. 
Interestingly, methylation of lysine 9 on Histone H3 and slencing is impaired in yeast lacking 
functional RNAi componernts such as Dicer, RDRP and Argonaute (61, 62).
    Additionally, transcripts complementary to silenced centromeric sequences tend to 
accumulate In RNAi mutant backgrounds, suggesting that RNAi components respond to 
endogenous dsRNAs produced at centromeres, silencing centromeric sequences (61). 
    It was discovered recently that RNAi components are also required to initiate silencing at 
the yeast mat locus.  Fission yeast can exist in a haploid state, or in a diploid state -- which is 
formed when two haploid cells fuse.  This fusion can only occur among two haploid cells 
that are of different mating types.  The mating type of the haploid cells is determined by a 
single locus, termed the mating type locus (mat).  The mat region consists of three loci, two 
of which are always silent and are required for the switching of the transcriptionally active 
locus.  Repression of transcription from the mat locus is essential for mating and is 
accompanied by changes in chromatin structure  (63, 64).
    RNAi components function to initiate heterochromatin formation at the mat locus.  
Mutants in yeast RNAi machinery failed to initiate heterochromatin assembly after removal 
of epigenetic markers by the use of the drug trichostatin A.  Additionally, the levels of H3 
lysine 9 methylation as well as Swi6, a heterchromatin protein, were greatly reduced at the 
mat locus in RNAi mutants (60).
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CONCLUSION
    RNA-mediated gene silencing has become an important tool to analyze gene function in 
many organisms as well as in mammalian tissue culture systems.  As genome sequences 
become readily available, RNAi makes the ability to analyze the function of each and every 
gene an attainable goal.  Moreover, the ability to readily silence specific genes holds promise 
in designing effective therapies to combat a range of illnesses.  The continued identification 
of genes required for RNAi should further our understanding of the mechanisms of RNAi .
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    Table 1.1: Proteins implicated in RNAi and related RNA silencing phenomena
C. elegans Drosophila Humans
Dicer RNase: DCR-1 Dicer Dicer
RNA-dependent RNA polymerases: EGO-1, RRF-1, RRF-3   
Proteins with PAZ/piwi domains: RDE-1 AGO2, Piwi,
Aubergine
eIF2C1/2
Nucleases: MUT-7 Tudor-SN
Helicases: MUT-14, DRH-1/2 p68, Spindle-E 
 
Chromatin modifiers: MES-3, -4, -6   
dsRNA-binding protein: RDE-4 R2D2
Nonsense-mediated decay SMG2, SMG-5, SMG-6   
Other proteins: SID-1 FMRP, dFXR, VIG
Plants Fungi
Dicer RNase: CAF/Sin-1 Dicer
RNA-dependent RNA polymerases: SGS2/SDE1 QDE1, RDRP, RrpA
Proteins with PAZ/piwi domains: AGO1, AGO4 QDE2, Ago1, Ago2
Nucleases: WEX-1  
Helicases: MUT6, SDE3 QDE3
Chromatin modifiers: DDM1, MET1
dsRNA-binding protein:
Nonsense-mediated decay
Other proteins: SGS3, HEN1
For references, see text and 2, 65, 66,  67,  68,  69, 70,  71,  72, 73,  74, 75,  76,  77,  78, and  79
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Figure 1.1.   Model for mRNA degadation in the cytoplasm by RNAi.
Introduced dsRNAs (red) are recognized by RDE-4/R2D2, a dsRNA binding protein.  These 
dsRNAs are then processed by Dicer into 21-23nt duplexes that can associate with an 
enzyme complex called RISC.  After unwinding of the siRNAs, RISC becomes competent to 
target homologous mRNA transcripts for degradation. 
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Figure 1.2.  Model of RdRP Activity.
Amplification of dsRNA by an RNA-dependent RNA polymerase in certain organisms, new 
dsRNAs can be generated by RDRPs, primed by siRNAs on mRNA targets.  The new 
dsRNAs can be used subsequently by Dicer to create more siRNAs, which can lead to 
additional rounds of amplification.
25
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Figure 1.3.  Model for gene silencing in the nucleus by RNAi.
RNAi can also silence the transcription of targeted genes in certain organisms.  In this model 
a signal can direct a putative nuclear RNAi silencing complex (NRISC), composed of 
chromatin modifying proteins, to the targeted locus, silencing gene expression at the level of 
transcription.
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CHAPTER II:  NUCLEAR RNAI PHENOMENA IN ANIMALS
INTRODUCTION
    RNA interference (RNAi) may be one of the oldest host defense responses known to date 
(1, 2). RNAi and similar phenomena in other organisms are believed to be parts of an ancient 
pathway to both combat foreign nucleic acids and prevent the expression of aberrant RNAs
(3, 4). Introduction of double-stranded RNA (dsRNA) has been found to result in the 
degradation of targeted mRNAs in the cytoplasm (5). This response effectively silences gene 
activity through the depletion of mRNAs that are necessary for producing protein. The exact 
mechanism underlying RNAi still remains unclear, however, some details have emerged over 
the past few years. This review will summarize what is currently known about the 
mechanism of RNAi and will highlight recent evidence that it may also function in the 
nucleus to silence transcription.
DISCOVERY OF RNAI
    Early evidence that RNA could elicit gene silencing in animal cells came from work by 
Guo and Kemphues, who used antisense RNA to reduce gene expression in the nematode 
Caenorhabditis elegans (C elegans) and were surprised to find that sense RNA was equally 
effective (6). Subsequently, Fire et al tested whether a very small amount of dsRNA may be 
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the effective agent in these experiments (5). A mixture of both sense and antisense RNA, 
resulting in dsRNA, gave a vastly more potent effect than either strand alone; so potent that 
even substoichiometric amounts of dsRNA elicited a penetrant effect. Subsequently, a 
number of previously known DNA sequence identity-dependent silencing phenomena have 
been found to share RNAi-like mechanisms, including co-suppression in plants and animals, 
and quelling in fungi (7). RNAi has since become widely used to suppress the function of 
specific genes. In the age of genomics, RNAi has proved a valuable tool that enables 
researchers to study a number of important processes such as cell death, development and 
cancer (1).
RNAI IN THE CYTOPLASM
    Recent genetic and biochemical research in several systems has greatly improved our 
understanding of how RNAi works (Figure 2.1). A dsRNA-binding protein recognizes 
introduced dsRNAs that are typically several hundred nucleotide pairs long (8). This dsRNA-
binding protein associates with Dicer, an RNaseIII-related enzyme, that dices the introduced 
dsRNA into small duplexes (21 to 25 nucleotides long) (8, 9, 10, 11). These small duplexes, 
called small interfering RNAs (siRNAs), then act as guides in association with a large protein 
complex to target transcripts for degradation. The siRNA/protein complex is termed an 
RNA-induced silencing complex (RISC) (12, 13, 14) and only becomes competent to target 
degradation of mRNAs upon ATP-dependent unwinding of the siRNAs (15). Concentrations 
as low as a few molecules of dsRNA per cell can elicit a strong and persistent response; this 
is likely to be a result of catalytic action by RISC (2, 5). In some organisms, it may also be a 
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result of an amplification mechanism in which an RNA-dependent RNA polymerase uses the 
target mRNA as a template to synthesize more dsRNA, using siRNAs as primers for new 
dsRNA production (16, 17).
    Many of the cellular components required for RNAi have been identified (18, 19). Exactly 
how the bulk of these components function in RNAi is not yet clear, and determining what 
roles they play is an ongoing challenge.
    Long dsRNAs cannot be used for gene silencing in all organisms, as some, including 
mammals, possess dsRNA defense mechanisms. Such mechanisms result in sequence-
nonspecific effects, thereby limiting the utility of long dsRNAs as a gene-silencing tool. 
Fortunately, siRNAs alone are able to elicit a potent and effective RNAi response, 
presumably bypassing the dicing step and directly loading onto RISC without triggering the 
dsRNA defense mechanisms (20, 21, 22, 23, 24).
    As RNAi and other sequence identity-dependent silencing phenomena share a remarkable 
degree of similarity, these diverse gene-silencing events are suspected to be modern versions 
of an ancient pathway that was used to regulate gene expression (25-30). Co-suppression in 
plants and quelling in fungi, for instance, share several features in their RNA-mediated 
responses (1). Co-suppression has been found to work, at least in part, post-transcriptionally. 
Many of the proteins involved in post-transcriptional gene silencing (PTGS) and RNAi are 
conserved (18, 19, 31). Moreover, plants undergoing PTGS have been found to possess small 
RNAs, approximately 25 nucleotides in length, which were absent in non-silenced control 
31
plants (32). As in animals, these small RNAs were found to be complementary to both the 
sense and antisense strands of the silenced gene. Small RNAs have been identified more 
recently in extracts of C elegans and Drosophila (10, 13, 14). 
    One surprising aspect of RNAi is that the effect can spread between tissues; introducing 
dsRNA in one part of an organism may lead to silencing of the targeted gene in another (5, 
33). Proteins specifically required for the spreading effect include a predicted transmembrane 
protein that may form a channel or act as a receptor for dsRNA, siRNA, or an as yet 
undiscovered RNAi signal (34).  Similarly, the ability of suppression to spread is also a 
feature of PTGS; in plants, tissue from a silenced donor, grafted to an unsilenced plant, can 
lead to silencing in the host (35).
RNAI IN THE NUCLEUS
Recent work has suggested that RNAi in non-plant systems may, in addition to eliminating 
specific pools of mRNA in the cytoplasm, also work by preventing the production of new 
mRNA by epigenetic silencing of gene expression in the nucleus.
    Epigenetic regulation refers to heritable changes in gene expression, without changes in 
gene sequence, which usually occur through modifications of chromatin (36). The eukaryotic 
nucleus contains large amounts of DNA that must be efficiently packaged into a very small 
space. Mechanisms to remodel chromatin at specific loci, thus rendering the DNA accessible 
to the transcriptional machinery, have developed in eukaryotic cells. Modifications to 
histones can regulate the availability of DNA by controlling the condensed state of chromatin 
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-- converting chromatin from a closed, heterochromatic state to an open, euchromatic state. 
Distinct histone modificationscan act sequentially or in combination to form a 'histone code' 
that dictates whether DNA is either accessible or tightly compact.  These modifications 
include covalent modifications, including methylation or acetylation, of specific amino acid 
residues on one or more histone tails (36,37).  In plants, DNA-mediated gene silencing can 
be epigenetic in nature; it has recently become clear that this can also be true for RNA-
mediated gene silencing. RNAi and co-suppression of endogenous genes by high copy 
number transgenes have both been found to work transcriptionally, as well as post-
transcriptionally (38, 39). Upon introduction of high copy number transgenes or dsRNA, 
PTGS occurs when there is sequence identity within the coding sequence, while 
transcriptional gene silencing (TGS) occurs when the sequence identity occurs within the 
promoter (40, 41). TGS in plants requires genes that are implicated in modifying chromatin 
structure and is also known to involve DNA methylation (42).
    DNA methylation does not appear to occur in certain animals, including C elegans and 
Drosophila, nor in certain fungi (43). This has raised the question of whether dsRNA only 
silences gene activity in the nucleus of plants. An answer to this question has begun to 
emerge from several studies published over the past year.
CHROMATIN MODIFICATION AND RNAI IN ANIMALS
    The fact that RNAi may also act by modifying chromatin has been suggested since, in 
animals, a phenotype induced by RNAi sometimes persists through additional generations 
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and some genes required for RNAi are also required to maintain chromosomal stability (33, 
44).
    Certain chromatin-modifying proteins have been implicated in RNAi in C elegans (45).  
The introduction of dsRNAs that target components of the RNAi machinery itself can, at 
least in some cases, prevent RNAi from functioning (9, 45, 46, 47).  In C elegans, this effect 
has been exploited to identify genes that may play roles in RNAi (45). Several genes 
identified by this method encode proteins that are predicted to associate with chromatin, 
raising the possibility that RNAi may work at the level of chromatin in animal cells, as it 
does in plants. Mutations in at least three of these genes have confirmed their roles in RNAi; 
this includes genes that encode proteins homologous to Drosophila Polycomb-group 
proteins, which function to repress gene expression through the modification of chromatin 
(48).
    Recent work using Drosophila has implicated a protein called Piwi in the silencing of 
targeted genes during high copy number transgene-induced silencing (49). Piwi is a homolog 
of the C elegans protein RNAi- defective 1 (RDE-1) and belongs to a large family of proteins, 
many of which are required for RNAi in diverse organisms (50-52). In piwi mutants of 
Drosophila, PTGS is greatly impaired and siRNAs corresponding to the target gene are 
absent (49). High copy number transgenes induce not only post-transcriptional but also 
transcriptional gene silencing in Drosophila (53). Interestingly, piwi mutants are also 
defective in transcriptional gene silencing. 
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    Since Drosophila TGS is dependent on Polycomb-group proteins, it is tempting to 
speculate that dsRNA might elicit Polycomb-dependent chromatin modifications and gene 
silencing in flies and worms (49, 53).  To date, however, TGS has only been assayed in flies 
and only after transgene-induced silencing, not after the introduction of dsRNA. Polycomb-
dependent silencing probably does not work by DNA methylation in flies and worms, since 
little to no DNA methylation can be detected in these organisms (43).
CHROMATIN MODIFICATION AND RNAI IN FISSION YEAST
Recent work has demonstrated that endogenous dsRNAs result in gene silencing in the 
fission yeast Schizosaccharomyces pombe (S pombe) (54).  Centromeric DNA is normally 
silenced in S pombe and transgenes inserted into centromeric regions are not expressed.
Centromeric silencing is dependent on RNAi machinery, as loss of genes homologous to 
those required for RNAi in animal systems can result in expression of centromeric 
transgenes. Centromeric DNA is normally flanked by silent, repetitive sequences and loss of 
the RNAi machinery also results in the abnormal production of transcripts deriving from both 
strands of the repeat sequences. Wild-type fission yeast do not accumulate such transcripts, 
and the dependence of the RNAi machinery on their disappearance suggests that dsRNAs 
normally produced by repetitive sequences are degraded by the RNAi machinery. In 
concordance with this, others have detected siRNAs derived from centromere repeat 
sequences in wild-type S pombe (55). 
    In addition, RNAi in fission yeast functions to repress transcription in the nucleus. 
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Silenced, centromeric sequences have covalent histone H3 modifications (eg, methylation of 
lysine 9) characteristic of silenced heterochromatin; centromere-homologous repeats are 
sufficient to induce such chromatin modifications elsewhere in the genome (54, 56).  Loss of 
the RNAi machinery results in histone H3 modifications characteristic of non-silenced 
chromatin at centromeric sequences. These results suggest that dsRNAs derived from the 
repeat sequences in centromeres are processed into siRNAs that serve to target a 
methyltransferase to a corresponding site in the centromeric region (54, 55, 56).  Recruitment 
of a methyltransferase could lead to covalent modification of histone H3 and the subsequent 
formation of silent chromatin. While the loss of RNAi components leads to derepression of 
centromeric DNA, the exact molecular mechanism by which this occurs remains to be 
determined.
    Upon chromatin modification directed by the RNAi machinery, other machinery takes 
over to maintain the repressed state. Histone H3 methylated at lysine 9 can recruit the 
heterochromatin protein Swi6/HP1 (56). After silencing has been established, RNAi 
components become dispensable for maintenance of the repressed state. Instead, Swi6/HP1 is 
essential for the silenced state of chromatin to be inherited through mitosis and meiosis (56). 
CONCLUSION
    RNA-mediated gene silencing has become an important tool to analyze gene function in 
many organisms. As genome sequences become available, RNAi makes determining the 
function of each and every gene a realistic goal. Moreover, the ability to readily silence 
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specific genes holds promise for designing effective therapies to combat a host of ailments. 
RNA-mediated gene silencing also plays a critical role in physiological gene silencing in a 
diverse range of organisms. As a result, there is much interest in understanding the 
mechanism by which RNA interference results in silencing.
    Much research evidence has been produced in the past several years to extend our 
understanding of how RNAi functions. Until recently, dsRNA had been predicted to act 
exclusively at the post-transcriptional level to target mRNA stability. Recent work, however, 
has uncovered an additional role for dsRNA in regulating transcription via remodeling of 
chromatin. While the exact mechanisms behind chromatin silencing are not yet clear, the 
notion that RNA may direct chromatin modifications at specific sites along a chromosome is 
intriguing.
    New developments in RNAi are likely to be closely watched, and as the molecular 
mechanisms of RNAi become fully understood, we will ultimately be better placed to 
understand genome 
37
REFERENCES
1. Sharp, P. A. (1999) Genes Dev 13, 139-41.
2. Tijsterman, M., Ketting, R. F. & Plasterk, R. H. (2002) Annu Rev Genet 36, 489-519.
3. Plasterk, R. H. (2002) Science 296, 1263-5.
4. Vazquez Rovere, C., del Vas, M. & Hopp, H. E. (2002) Curr Opin Biotechnol 13,
167-72.
5. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. & Mello, C. C. 
(1998) Nature 391, 806-11
6. Guo, S. & Kemphues, K. J. (1995) Cell 81, 611-20.
7. Zamore, P. D. (2002) Science 296, 1265-9.
8. Tabara, H., Yigit, E., Siomi, H. & Mello, C. C. (2002) Cell 109, 861-71.
9. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. (2001) Nature 409,
363-6.
10. Ketting, R. F., Fischer, S. E., Bernstein, E., Sijen, T., Hannon, G. J. & Plasterk, R. H. 
(2001) Genes Dev 15, 2654-9.
11. Knight, S. W. & Bass, B. L. (2001) Science 293, 2269-71.
12. Elbashir, S. M., Lendeckel, W. & Tuschl, T. (2001) Genes Dev 15, 188-200.
13. Hammond, S. M., Bernstein, E., Beach, D. & Hannon, G. J. (2000) Nature 404, 293-
6. 
38
14. Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. (2000) Cell 101, 25-33.
15. Nykanen, A., Haley, B. & Zamore, P. D. (2001) Cell 107, 309-21.
16. Smardon, A., Spoerke, J. M., Stacey, S. C., Klein, M. E., Mackin, N. & Maine, E. M. 
(2000) Curr Biol 10, 169-78.
17. Lipardi, C., Wei, Q. & Paterson, B. M. (2001) Cell 107, 297-307.
18. Hannon, G. J. (2002) Nature 418, 244-51.
19. Hutvagner, G. & Zamore, P. D. (2002) Curr Opin Genet Dev 12, 225-32.
20. Yang, D., Lu, H. & Erickson, J. W. (2000) Curr Biol 10, 1191-200.
21. Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W. & Tuschl, T. (2001) 
Embo J 20, 6877-88.
22. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl, T. 
(2001) Nature 411, 494-8.
23. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. (2002) Cell
110, 563-74.
24. Shi, Y. (2003) Trends Genet 19, 9-12.
25. Baulcombe, D. C. (1996) Plant Mol Biol 32, 79-88.
26. Cogoni, C. & Macino, G. (1999) Curr Opin Microbiol 2, 657-62.
27. Ngo, H., Tschudi, C., Gull, K. & Ullu, E. (1998) Proc Natl Acad Sci U S A 95,
14687-92.
39
28. Kennerdell, J. R. & Carthew, R. W. (1998) Cell 95, 1017-26.
29. Wianny, F. & Zernicka-Goetz, M. (2000) Nat Cell Biol 2, 70-5.
30. Li, Y. X., Farrell, M. J., Liu, R., Mohanty, N. & Kirby, M. L. (2000) Dev Biol 217,
394-405.
31. Plasterk, R. H. & Ketting, R. F. (2000) Curr Opin Genet Dev 10, 562-7.
32. Hamilton, A. J. & Baulcombe, D. C. (1999) Science 286, 950-2.
33. Grishok, A., Tabara, H. & Mello, C. C. (2000) Science 287, 2494-7.
34. Winston, W. M., Molodowitch, C. & Hunter, C. P. (2002) Science 295, 2456-9.
35. Palauqui, J. C., Elmayan, T., Pollien, J. M. & Vaucheret, H. (1997) Embo J 16, 4738-
45.
36. Ahmad, K. & Henikoff, S. (2002) Cell 111, 281-4.
37. Strahl, B. D. & Allis, C. D. (2000) Nature 403, 41-5.
38. Vaucheret, H., Beclin, C. & Fagard, M. (2001) J Cell Sci 114, 3083-91.
39. Fire, A. (1999) Trends Genet 15, 358-63.
40. Waterhouse, P. M., Graham, M. W. & Wang, M. B. (1998) Proc Natl Acad Sci U S A
95, 13959-64.
41. Mette, M. F., Aufsatz, W., van der Winden, J., Matzke, M. A. & Matzke, A. J. (2000) 
Embo J 19, 5194-201.
40
42. Matzke, M. A., Aufsatz, W., Kanno, T., Mette, M. F. & Matzke, A. J. (2002) Adv 
Genet 46, 235-75.
43. Paszkowski, J. & Whitham, S. A. (2001) Curr Opin Plant Biol 4, 123-9.
44. Ketting, R. F., Haverkamp, T. H., van Luenen, H. G. & Plasterk, R. H. (1999) Cell
99, 133-41
45. Dudley, N. R., Labbe, J. C. & Goldstein, B. (2002) Proc Natl Acad Sci U S A 99,
4191-6.
46. Grishok, A., Pasquinelli, A. E., Conte, D., Li, N., Parrish, S., Ha, I., Baillie, D. L., 
Fire, A., Ruvkun, G. & Mello, C. C. (2001) Cell 106, 23-34.
47. Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R. & Hannon, G. J. (2001) 
Science 293, 1146-50.
48. Pirrotta, V. (2002) Cell 110, 661-4.
49. Pal-Bhadra, M., Bhadra, U. & Birchler, J. A. (2002) Mol Cell 9, 315-27.
50. Cogoni, C. & Macino, G. (2000) Curr Opin Genet Dev 10, 638-43.
51. Tabara, H., Sarkissian, M., Kelly, W. G., Fleenor, J., Grishok, A., Timmons, L., Fire, 
A. & Mello, C. C. (1999) Cell 99, 123-32.
52. Fagard, M., Boutet, S., Morel, J. B., Bellini, C. & Vaucheret, H. (2000) Proc Natl 
Acad Sci U S A 97, 11650-4.
53. Pal-Bhadra, M., Bhadra, U. & Birchler, J. A. (1997) Cell 90, 479-90.
54. Volpe, T. A., Kidner, C., Hall, I. M., Teng, G., Grewal, S. I. & Martienssen, R. A. 
(2002) Science 297, 1833-7.
41
55. Reinhart, B. J. & Bartel, D. P. (2002) Science 297, 1831.
56. Hall, I. M., Shankaranarayana, G. D., Noma, K., Ayoub, N., Cohen, A. & Grewal, S. 
I. (2002) Science 297, 2232-7 
 
.
42
Figure 2.1. Mechanism of RNAi. 
The figure illustrates a working model combining results from various organisms (see text 
for details and references). Proteins and protein activities are shown as balls; identified 
proteins or activities are labeled, some speculated proteins and complexes are unlabeled, and 
ATP-dependent steps are marked. Whether dsRNAs or siRNAs enter the nucleus is not yet 
clear.  Note that Dicer is known to associate with RISC but is not required for RISC activity. 
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CHAPTER III:  RNAI SILENCING METHODS
INTRODUCTION
    The introduction of double-stranded RNA (dsRNA) into C. elegans hermaphrodites results 
in the rapid and sequence-specific degradation of endogenous mRNAs (1, 2). This RNA-
mediated interference, or RNAi, effectively shuts down expression of the target gene and can 
phenocopy loss of function mutations. RNAi is also remarkably potent, requiring only 
substoichiometric amounts of dsRNA to elicit a response (1).  Another notable aspect of 
RNAi in C. elegans is that it is systemic in that the silencing can spread between tissues
throughout the adult as well as its progeny (1, 3, 4).  Many neurons, however, are refractory 
to the spreading effect in wild-type backgrounds (5). 
    Although discovered in C. elegans, the use of double-stranded RNA to silence gene 
expression has quickly become a widely used tool to study gene function in a number of 
organisms, including mammals (6, 7).  RNAi may have evolved from an ancient 
phenomenon used to regulate gene expression and combat transposable elements and viruses 
(8).  
    The ability to use RNAi to target single or multiple transcripts and the ability to apply 
RNAi to large-scale genomic screens further highlight the power of this technique (9, 10, 11, 
12).
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MATERIALS
Wild-type C. elegans
NGM agar plates: 2.5 g peptone, 17 g agar, 3 g NaCl, 975 ml dH20.  Autoclave (30 minutes). 
Let cool to 55ºC and add the following sterile solutions: 1 ml of 5 mg/ml cholesterol (stock in 
EtOH), 1 ml of 1M CaCl2, 1 ml of 1M MgSO4, 25 ml of 1M KH2PO4
OP50 E. coli
Agarose, low EEO electrophoresis grade (Fisher Scientific, Suwanee,GA)
Large plastic Petri dishes, 100x15 mm (Fisher Scientific, Suwanee,GA)
Sterile M9 buffer:  3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 ml of 1M MgSO4 fill to 1L with 
dH20
15 ml polypropylene tube 
50-100-20 buffer: 50 mM Tris-HCl, 100 mM NaCl, 20 mM EDTA, pH 7.5
50-100-20 + SDS + proteinase K: 1% SDS (sodium dodecyl sulphate), 200 µg/ml proteinase 
K in 50-100-20 Buffer
Phenol:Chloroform (1:1)
3M sodium acetate, pH 5.2
100% ethanol
Worm pick: 36 gauge platinum wire attached to glass Pasteur pipete  (Fisher Scientific, 
Suwanee,GA) 
TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH7.6
DNase-free RNase A
Oligonucleotide primers specific to target gene
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Oligo (dT)12-18 (500µg/ml)
Sterile DEPC H20
5X First Strand Buffer, supplied with enzyme (Stratagene, La-Jolla, CA)
 0.1M DTT, supplied with enzyme (Stratagene, La-Jolla, CA)
10 mM dNTP stock in DEPC-dH2O (Stratagene, La-Jolla, CA)
SuperScript II enzyme (200 U/µl) (Stratagene, La-Jolla, CA)
0.5 M EDTA
25mM dNTPs
Taq polymerase
Polymerase Chain Reaction (PCR) thermocycler and supplies
PCR purification kit (Qiagen, Valencia, CA)
Phenol:chloroform:isoamylalcohol (25:24:1)
Chloroform
10 M NH4AC
70% EtOH
Agarose gel electrophoresis apparatus 
UV transilluminator
Ethidium bromide (EtBr), (0.3 µg/ml)
Ultraviolet (UV) spectrophotometer 
Gel Extraction kit (Qiagen, Valencia, CA)
T7 transcription kit (Ambion Megascript T7, Austin, TX or Promega, T7 Ribomax, Madison, 
WI)
Speed vacuum apparatus
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Borosilicate capillaries model 1B100F (World Precision Instruments, Sarasota, FL) 
Needle puller (Sutter Instruments, Novato, CA)
Halocarbon oil, series 700 (Sigma, St. Louis, MO)
Injection pads (24 X 50mm #1 cover slip with 2% agarose)
RNAi soaking buffer: 0.05% Gelatin, 5.5mM KH2PO4, 2.1mM NaCl, 4.7mM NH4Cl, 3mM 
spermidine.  Add spermidine fresh before each use.
NGM plates +1 M IPTG + ampicillin poured fresh (1-3 days before use)
Ampicillin 100mg/ml
LB ampicillin agar plates (50µg/ml)
LB tetracycline agar plates (12.5µg/ml)
Sterile, RNase free dH20
Siliconized 0.6 ml eppendorf tubes
Siliconized 200 µl pipette tips
C. elegans feeding library (MRC Geneservice)
Isopropyl bD-thiogalactopyranoside (IPTG)
METHODS
    The methods below outline (1) Preparation of genomic DNA from C. elegans, (2) dsRNA 
synthesis, and (3) RNA interference methods. Methods for handling C. elegans are described 
in Sulston and Hodgkin (13) and detailed methods for injection are described in Mello and 
Fire (14).
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Preparation of genomic DNA from C. elegans
1.  Grow up 1-2 large plates of worms on NGM plates, using agarose in place of
      the agar.
2. Wash worms off of a recently starved plate (to avoid excess bacteria) using
     sterile M9 buffer, into a 15 ml polypropylene tube. 
3.  Pellet worms by centrifugation and carefully discard supernatant.
4.  Wash worms with 10 ml of 50-100-20 buffer.
5.  Pellet worms by centrifugation and carefully discard supernatant.
6.  Add 2 ml of 50-100-20 + 1% SDS + 200 µg/ml Proteinase K and incubate at  
  65˚C.
7.  Periodically agitate until suspension is viscous (use gentle agitation to avoid
      shearing DNA).  This takes about 30 minutes.
8.  Add 2 ml of phenol:chloroform and invert gently for 5 minutes.
9.  Centrifuge to separate phenol:chloroform and aqueous phases.
10. Transfer top (aqueous) phase to a clean 15 ml tube.
11.  Add 270 µl of 3M sodium acetate (this results in a final concentration of 0.4M
       sodium acetate).
12.  Add 2.5 volumes of 100% ethanol.
13.  Wind out DNA precipitate onto the tip of a sealed glass Pasteur pipette (DNA
        is visible as thin threads).
14.  Dissolve DNA in 400 µl of TE (see Note 1). 
15.  Add RNase to 20 µg/ml final concentration.
49
16.  Incubate at 37˚C for 20 minutes.
17.  DNA is sufficiently clean for use as template in PCR.  Store at 4C 
       (see Note 2). 
 dsRNA synthesis
Primer design
    Design primers to amplify ~1kb of mostly coding sequence (see Note 3), although 200-500 
bp of target sequence often works well and may also reduce the chance of targeting other 
homologous transcripts. Be sure to target mostly exonic sequences and ensure that you are 
not targeting other homologous transcripts (see Note 4). 
First strand cDNA Synthesis (if unable to use genomic DNA
    In those cases where only small exons separated by large introns are available, cDNA must 
be used to ensure you have sufficient exonic sequence to target.
    Before starting, make sure that all of the materials and reagents are sterilized and/or 
nuclease free. 
1. Mix:          1 µl  of Oligo (dT)12-18 (500µg/ml)
                      1-5 µg of mRNA 
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                      Sterile DEPC H20 to 12 µl
2. Heat the mixture to 70˚C for 10 minutes, and then quickly chill on ice.  
3. Centrifuge briefly to collect mixture at bottom of tube.
4. Add the following:
4 µl of 5X First Strand Buffer
2 µl of 0.1 M DTT 
1 µl of mixed dNTP stock
5. Mix the contents and centrifuge briefly to collect.  Place tube at 42˚C for 2
     minutes to equilibrate temperature.
6. Add 1µl of SuperScript II enzyme (200 U/µl) per each µg of mRNA used above
     to the mix.
7. Incubate at 42˚C for 1 hour.
8. Add 4µl of 0.5M EDTA or place tube at 70˚C for 15 minutes in order to 
     terminate the reaction.
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9. Store cDNA at -20˚C until use.
PCR
    Amplification is performed in two steps.  Designing an in vitro transcription template from 
a two-step PCR makes synthesizing multiple primers less expensive and may increase the 
yield of PCR products bearing complete T7 sites.  The first step below uses two 35 base-pair 
primers, and each primer contains 15 bases of T7 sequence plus 20 bases of sequence from 
the gene of interest (see Note 5).
Example:
partial T7              gene of interest                    
forward primer 5' CGACTCACTATAGGGCGATGAGGGCCTATTTATTC 3'
reverse primer 5' CGACTCACTATAGGGGAGAAAGTACACGATATAGC 3'
    The first PCR product is cleaned using the Qiagen PCR Purification kit (as per 
manufacturer’s instructions) and eluted in 33 µl final volume.  One-tenth of the recovered 
product is analyzed on an agarose gel (Figure 3.1A) and visualized using EtBr and UV 
illumination.
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    The second PCR uses the same primer on each end -- a primer containing the full T7 
polymerase promoter plus restriction sites for use with cloning: EcoRI, XbaI, and HindIII 
(see Note 6):
EXHT7:        5' ATAGAATTCTCTAGAAGCTTAATACGACTCACTATAGGG 3'
One-tenth of the recovered product is analyzed on an agarose gel (Figure 3.1B) and 
visualized using EtBr and UV illumination.
In vitro transcription
    The second PCR product is then gel purified (Qiagen Gel Extraction kit, as per 
manufacturer’s instructions) and 1-2 micrograms of PCR product are used as template for 
transcription.  Commercially available in vitro transcription kits such as Ambion’s 
Megascript-T7 kit or Promega’s T7 Ribomax kit can be used to get high yields of dsRNA 
(see Note 7).
RNA recovery
    Pass the RNA through a Qiagen PCR Purification column (treating the RNA as if it were a 
PCR product) to purify the RNA. RNA-specific columns can be used instead, although these 
are more expensive. Alternatively, dsRNA can be purified using phenol-chloroform 
extraction followed by ethanol precipitation (see 3.2.7).  Assess dsRNA integrity on an 
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agarose gel (Figure 3.1C) and determine concentration using a UV spectrophotometer. 
Storage
    Mix the resulting solution with 2 volumes 100% EtOH and store at -80ºC.  Before use, the 
EtOH should be evaporated in a speed-vaccum apparatus and the dsRNA pellet can be 
resuspended in sterile distilled water at your desired concentration.
Phenol-Chloroform extraction and Ethanol precipitation
    Instead of using expensive columns (see 3.2.5) you can purify your dsRNA using phenol-
chloroform extraction followed by ethanol precipitation.
1.  Add an equal volume of phenol:chloroform:isoamylalcohol (25:24:1) to the in
     vitro transcription reaction.
2.  Mix (vortex) the contents of the tube until an emulsion forms.
3.  Centrifuge the mixture at 12,000 rpm for 15 seconds in a microcentrifuge at
      rooom temperature.
4.  Transfer upper (aqueous) phase containing dsRNA to a fresh tube. Discard
      the interface and the lower (organic) phase.
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5.  Add equal volume of chloroform and repeat extraction steps (steps 2-4).
6.  Add 1/3 volume of 10M NH4AC. 
7.  Add 2.5 volumes of 100% EtOH and put at –20˚C for 30 minutes (dsRNA can
     be stored at this step at –20˚C if desired).
8.  Spin down for 10 minutes at 12,000 rpm in microcentrifuge at 4˚C to pellet 
      dsRNA.
9.  Wash pellet with 70% EtOH.
 10.  Air dry pellet. 
 11.  Resuspend in 100µl of TE, pH 7.6.
 12.  dsRNA should be stored at –20ºC in 1-2 volumes of 100% EtOH.
Microinjection
    dsRNA for microinjection can be injected anywhere in the body cavity or gonad of the C. 
elegans hermaphrodite (1). Additional details can be found in Mello and Fire (14).
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Preparing and storing needles
1. Pull capillaries to a finely tapered tip using needle puller. 
2. Use a Petri dish containing a strip of modeling clay to hold the needles.  If kept
    dust-free, needles can be stored indefinitely.
Injection pads 
1. A drop of 2% agarose (in dH2O) is flattened between two 24 X 50mm #1 cover 
    slips.
2. After hardening, remove top cover slip and let pad dry in open air
   (Alternatively, pads can be baked at 60ºC for 1 hour).  If letting the pads air dry,
    they should be made at least one day prior to use.  Pads made either way can
     be stored for several weeks at room temperature.
3. Inject dsRNA solution into hermaphrodite gut or gonad.
Loading and breaking the needle
1. Place a 0.5 µl drop of the dsRNA solution on the back (blunt) end of the needle
     the needle contains an inner glass filament that will wick the dsRNA solution
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     to the tapered end.
2.  Load needle onto injection microscope.   Use the edges of the agarose 
     injection pad to gently break the needle.  This step here takes practice to 
     ensure that the needle doesn’t have too large an opening, which would tend 
      to damage the worms during injection (see Note 8).
Mounting and injecting worms 
1. Place a drop of Halocarbon oil on the pad.
2. Using a worm pick transfer young adult hermaphrodites to the oil drop on the
     pad (see Note 9).
3. Pat the animal down on the agarose pad with your pick until it is firmly stuck to
    the  pad.  Minimize the time that the worms spend drying out on the pad during
     injection to increase the viability of the worms.
Recovery
Put the pad under the dissecting scope and place a drop of M9 buffer on the oil drop 
containing your worms.  Your worms will rehydrate and begin to swim.  Transfer worms to a 
fresh NGM plate.
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Feeding
    RNAi can be performed in C. elegans by feeding RNAse III resistant bacteria expressing 
dsRNA to C. elegans (5).  A genomic feeding library has been constructed (15) and is 
available commercially.  The library consists of genomic fragments cloned into an IPTG 
inducible T7 polymerase vector (the PCR product made in 3.2.3 can also be cloned into this 
feeding vector).  The vectors are transformed into the RNAse III resistant bacterial strain.
1. Streak out –80ºC stock feeding strain that contains the desired construct
      onto LB tetracycline plates (tetracycline will select for feeding competent
      bacteria).
    2.   Pick a bacterial colony from streaked plates with a sterile toothpick (using
          sterile technique) and place it in ~2ml LB/amp (ampicillin will select for the
          cloned gene of interest). 
     3.  Shake overnight at 37oC.
     4.  Inoculate 2ml fresh LB plus ampicillin with 20µl of the overnight culture.
  Grow at 37ºC until optical density is between 0.35 and 0.40 (this usually
          takes about 3hrs).
     5.  Seed NGM+IPTG+Ampicillin plates with actively growing culture and allow
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          to dry at room temperature (this will happen anytime between 3 hours to
          overnight) (see Note 10).
      6.  Add worms to dsRNA producing bacteria and allow worms to feed.
           Transfer worms every 24hrs to new feeding plates (see Note 11).
Soaking
    RNAi can be performed in C. elegans by soaking worms in dsRNA (16), and this method 
has been used in large-scale screens (12).
1.  Pick 4 young adults onto a fresh unseeded NGM plate to clean off bacteria
     (see Note 12).
2.  Wash worms with a drop of M9 and allow them to crawl away.
3.  Add the 4 worms to 2µl of RNAi soaking buffer in 0.6 ml siliconized Eppendorf 
      tubes (final dsRNA concentration should be at 1mg/ml).
4. Place at 20ºC for 24hrs.
5.  Transfer worms to a fresh, seeded plate using siliconized pipette tips.
      Wash eppendorf tube with 100µl of M9 to ensure transfer of all of  the soaked worms.
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6.  Transfer to new plates daily and score progeny.
Notes
1. Swirl the tip of the glass Pasteur pipette containing the DNA in a microfuge tube 
containing 400 µl of TE.
2. Do not freeze genomic sample as thaw cycles can shear genomic DNA.  Multiple genomic 
DNA preparations can be used as templates when a product does not amplify from a single 
preparation.
3. Visit www.wormbase.org for gene structure information.
4. Visit http://www.sanger.ac.uk/cgi-bin/blast/submitblast/c_elegans for BLAST tools needed 
to search for and avoid dsRNAs that target other homologous transcripts.
5. When designing primers be sure to avoid creating primers that contain primer dimers.  
Also, primers should not have a high GC content (>50%) and be sure that your primers are 
also free from strong secondary structure.
6. These DNA templates can be easily cloned into the feeding construct (L4440) discussed in 
3.4.
7. Purchasing rNTPs, T7 polymerase, DNase, and RNase inhibitors separately and then 
purifying the dsRNA using phenol:chloroform followed by EtOH precipitation also works 
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well (see 3.2.7).
8. You can also dip needles in hydrofluoric acid to open needle tips.
9. Be sure to limit the amount of bacteria transferred as excess bacteria can make it difficult 
for the worms to adhere to the pad.
10.  Be sure all media for plates are cooled to 50°C before adding IPTG, ampicillin or 
tetracycline.
11.  You can also place young larvae on plates or have worms lay eggs onto the feeding 
plates for a couple of hours followed by removal of the mothers.
12. This protocol can be scaled up as necessary.
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Figure 3.1:  Production of dsRNA
(A) mlc-4 (1) and nmy-2 (2) PCR product amplified from genomic DNA with primers having 
partial T7 sequences. (B) mlc-4 and nmy-2 second round PCR product that have been gel 
purified using complete T7 primers and restriction sites. (C) Amplified and purified mlc-4 
and nmy-2 dsRNAs.  M is DNA marker in each panel.
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CHAPTER IV:  USING RNAI TO IDENTIFY RNAI COMPONENTS
INTRODUCTION
    RNA interference (RNAi) works in a remarkable variety of organisms, including animals, 
plants, fungi and protists (1-4).  RNAi can be used as a tool to phenocopy the loss of function 
of one specific gene at a time (5), and it has been exploited in screens designed to identify 
developmental genes, by injecting pools of multiple double-stranded RNAs (dsRNAs) into 
animals and examining phenotypes in their progeny (6-10).
    The process by which dsRNA silences gene activity is not completely understood, 
although the mechanism is known to involve cleavage of both the dsRNA and the 
corresponding endogenous mRNA into 21 to 25 nucleotide fragments (11-14).  Cleavage of 
the dsRNA in animal cells requires Dicer, a member of the RNase III family of nucleases 
(15-17).  To date, only a handful of other proteins have been implicated in RNAi in animal 
cells, and all of these are predicted to interact with RNA -- an RNaseD-like protein, an RNA-
dependent RNA polymerase-like protein and an eIF2C-like protein (18-20).  Some of the C. 
elegans smg genes, which participate in nonsense-mediated mRNA decay, are required for 
the RNAi effect to persist (21).  In plants and fungi, RNAi has been proposed to additionally 
involve chromatin, since RNAi-like phenomena require proteins predicted to interact with 
chromatin -- a SWI2/SNF2 component, a DNA methyltransferase and a DNA helicase-like 
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protein (22-25) -- as well as proteins predicted to interact with RNA (22, 26).  No such role 
for chromatin has yet been implicated in animal cells. 
    We have fortuitously identified a double-stranded RNA that acts as a potent suppressor of 
the RNA interference mechanism.  Here, we describe the method we used and additional 
genes with potential roles in RNAi that we have identified using this approach.
MATERIALS AND METHODS
Strains. 
C. elegans was maintained as in (27).  Strains and alleles used were Bristol Strain N2 (wild-
type), SS186: mes-2(bn11) unc-4(e120)/mnC1 dpy-10(e128) unc-52(e444)II, SS262: mes-
3(bn35) dpy-5(e61)I; sDp2(I;f), SS268: dpy-11(e224) mes-4(bn23) unc-
76(e911)V/nT1(IV;V), JK2663: dpy-11(e224) mes-4(bn67) V/nT1(IV;V), SS222: mes-
3(bn21)I, SS282: mes-6(bn64); dpy-11(e224)/nT1(IV;V), SS360: mes-6(bn66) dpy-
20(e1282)IV/nT1(IV;V).
dsRNA preparation.  
Templates for in vitro transcription were generated by a two-step PCR from wild-type 
genomic DNA.  Primers for the first step included 20 bases specific to the target sequence 
and 15 bases of the T7 sequence.  The resulting PCR product was purified using a Qiagen 
PCR Purification kit according to the manufacturer’s recommendations.  This product was 
used as a template for a second PCR using oligonucleotides containing the full-length T7 
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promoter sequence.  1-2µg of the product was then gel-purified and used as a template in an 
in vitro transcription reaction using Ambion’s T7 Megascript Kit according to the 
manufacturer’s recommendations.  The integrity of the dsRNA was assessed by gel 
electrophoresis and the concentration was determined by spectrophotometry.  For storage of 
dsRNAs, the resulting solution was mixed with 2 volumes of 100% ethanol and kept at –
80ºC.  RNAi-to-RNAi assays were performed by co-injecting 30ng/µL of target dsRNA (for 
example, mom-2) with 100ng/µL of test dsRNA (for example, mut-7) into either the gut or 
gonad of adult wild-type hermaphrodites.  For each experiment in Fig 4.3C, 500ng/µL 
dsRNA was injected.  
Soaking 
    Soaking experiments were performed by the method of Maeda et al. (10) with the 
following alterations: both wild-type and mutant worms were incubated together in 8µl of 
soaking buffer with either 100ng/µl or 800ng/µl dsRNA for 24 hours, and transfers to freshly 
seeded NGM plates were carried out daily.
RESULTS AND DISCUSSION
    During a pilot screen aimed at identifying genes with essential roles in embryogenesis, we 
found that one pool of eight dsRNAs that was expected to produce embryonic lethality did 
not (Figure 4.1A): injecting C. elegans adult hermaphrodites with a pool containing dsRNA 
corresponding to the essential gene glp-1 (28, 29) and seven other dsRNAs resulted only in 
viable embryos.  In contrast, injecting the glp-1 dsRNA alone resulted in a high degree of 
embryonic lethality (Figure 4.1B).  To determine whether the lethality produced by glp-
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1(RNAi) was being suppressed by a specific dsRNA in the pool, we coinjected glp-1 dsRNA 
with each other dsRNA from the pool.  We found that only injection of a dsRNA 
corresponding to the M04B2.3 gene could suppress glp-1 dsRNA-mediated lethality (Figure 
4.1C).  Additionally, removing the M04B2.3 dsRNA from the pool was sufficient to restore 
embryonic lethality upon injection (Figure  4.1D), indicating that the glp-1(RNAi) phenotype 
is not suppressed nonspecifically by coinjection of multiple other dsRNAs.
    M04B2.3 dsRNA might suppress glp-1(RNAi) by suppressing glp-1 loss of function.  
Alternatively, it might suppress glp-1(RNAi) by suppressing the RNAi mechanism.  To 
distinguish between these possibilities, we first tested whether M04B2.3 dsRNA could 
suppress glp-1 loss-of-function mutations.  Injection of M04B2.3 dsRNA failed to suppress 
the lethality produced by two glp-1 alleles, q231 and q224 (28) (data not shown).  Next, we 
determined whether M04B2.3 dsRNA suppresses the RNAi mechanism, by testing whether it 
could suppress the lethality produced by other dsRNAs.  We found that M04B2.3 dsRNA 
was able to suppress the lethality produced by RNAi of several structurally unrelated, 
essential genes (Figure 4.1E), suggesting that M04B2.3 dsRNA is a potent suppressor of the 
RNAi mechanism.  
    M04B2.3 appears to be relatively unique in its ability to suppress the phenotypes of 
coinjected dsRNAs, since none of the other genes tested in the pilot screen produced a 
similar effect.  The pilot screen comprised ten pools of eight dsRNAs, all of which 
correspond to transcripts that are enriched in C. elegans oocytes in comparison to somatic 
tissues (30).  Seven of the ten pools included dsRNAs corresponding to genes already known 
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to be essential for embryogenesis, and all of these pools, except the one that included 
M04B2.3 and glp-1, resulted in embryonic lethality (Figure 4.1A).  Injections of subsets of 
dsRNAs from each of these pools revealed that every dsRNA expected to produce embryonic 
lethality did so, with the exception of glp-1 dsRNA.  Since the pools included only one 
suppressor (M04B2.3) and 38 dsRNAs that neither produced lethality themselves, nor did 
they suppress the phenotypes of co-injected, previously-known lethal dsRNAs, we estimate 
that very few dsRNAs corresponding to germline-enriched transcripts can suppress RNAi in 
pools.
    Suppression of RNAi by M04B2.3 dsRNA might be caused by loss of M04B2.3 mRNA.  
Alternatively, the M04B2.3 dsRNA might suppress RNAi because it contains a specific 
dsRNA sequence that is a potent competitor for the RNAi machinery; to test this, we 
generated dsRNAs corresponding to the 5' and 3' halves of the M04B2.3 gene and coinjected 
either half with mom-2 or glp-1 dsRNAs. If a specific sequence in the M04B2.3 dsRNA is a 
strong competitor for the RNAi machinery, we would expect only the half that contained this 
sequence to suppress RNAi, whereas if M04B2.3 is required for RNAi, we would expect 
both halves to suppress RNAi.  We found that both of these dsRNAs suppressed the lethality 
produced by mom-2 and glp-1 dsRNAs (data not shown); this and further results below 
suggest that suppression is produced by loss of M04B2.3 mRNA.
    These results suggest that injecting multiple dsRNAs can be used as an efficient method to 
identify genes required for RNAi.  Others have found recently that RNAi of C. elegans and 
fly versions of Dicer and fly Argonaute2 can reduce the effectiveness of RNAi of particular 
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genes (15, 16, 31).  We asked whether RNAi of additional known components of the RNAi 
machinery could also suppress phenotypes associated with these dsRNAs.  dsRNAs 
corresponding to two genes required for RNAi, mut-7 and rde-1 (18, 20), were each 
coinjected with either mom-2 or hmp-2 dsRNA.  Like M04B2.3, both rde-1 and mut-7 were 
able to suppress the embryonic lethality produced by RNAi of mom-2 or hmp-2, whereas 
control dsRNAs could not (Figure 4.1F).  Based on these results and on our results from the 
pool from which M04B2.3 was identified, we conclude that injecting as many as eight 
dsRNAs at a time can be used as an efficient method to identify candidates for genes 
involved in the RNA interference mechanism in C. elegans.  For convenience, we refer to the 
injection of multiple dsRNAs for this purpose as an RNAi-to-RNAi assay.
    A BLAST search revealed that the M04B2.3 gene (Figure 4.2A) has strong similarity to a 
human gene, GAS41, which was found as an amplified gene in glioblastomas (32, 33).  We 
therefore refer to the M04B2.3 gene as gfl-1, for GAS41-like.  Both the human GAS41 and 
C. elegans GFL-1 proteins are predicted to associate with DNA, based on the presence of an 
acidic domain and on sequence similarity to a conserved domain of the predicted chromatin-
modifying protein TFIIF.  GAS41 has been found to bind another human protein, the 
leukemia translocation protein AF10, by yeast 2-hybrid, GST pulldown and co-
immunoprecipitation assays (34).  Since the human AF10 gene has strong similarity to a C. 
elegans gene, zfp-1 (both share predicted LAP/PHD finger, zinc finger and leucine rich 
domains; Figure 4.2B) we tested whether RNAi of zfp-1 also suppresses RNAi.  We found 
that injection of zfp-1 dsRNA suppressed the lethality produced by mom-2 and hmp-2 
71
dsRNAs (Figure 4.3A), suggesting that like gfl-1, the zfp-1 gene may also be required for 
RNAi.
    Two other human genes with sequence similarity to GAS41, AF-9 and ENL, encode 
proteins that can bind human Polycomb 3 (35).  We therefore tested whether C. elegans
polycomb-group genes are required for RNAi.  Only two Drosophila polycomb-group genes, 
Enhancer of zeste and extra sex combs, have recognizable C. elegans homologs, named mes-
2 and mes-6 respectively for their maternal effect sterile loss-of-function phenotypes (36, 37).  
MES-2 and MES-6 proteins exist in a complex with a novel protein, MES-3 (38).  mes-2, 
mes-3, mes-6, and a gene with some similarity to mes-2, called mes-4, are each required 
maternally for survival of larval germ cells (39, 40).  Loss of function of any of these four 
mes genes causes a defect in transgene silencing, a phenotype that has also been seen in 
mutants deficient in RNAi (20, 41).  We tested each of these four mes genes by the RNAi-to-
RNAi assay, and found that the lethality produced by mom-2 or pos-1 dsRNA was indeed 
suppressed by coinjection of mes-3, mes-4, or mes-6 dsRNA, but not by coinjection of mes-2 
dsRNA (Figure 4.3B), suggesting that mes-3, mes-4, and mes-6 may be required for RNAi, 
and that mes-2 is not.  
    As an important test of our proposal that certain of the mes genes play roles in RNAi, we 
determined whether worms bearing loss-of-function mutations in each of these genes are also 
RNAi-deficient.  We injected mom-2, hmp-2, or par-2 dsRNAs into homozygous mes mutant 
hermaphrodites at a dsRNA concentration typical for C. elegans RNAi experiments (6, 19) 
(see Materials and Methods).  Consistent with our RNAi-to-RNAi results, the lethality 
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produced by each dsRNA was suppressed in mes-3, mes-4 and mes-6 null mutants, and it was 
not suppressed in mes-2 null mutants (Figure 4.3C).  
    Our results appear to contradict some of the results of Tabara et al. (20), who reported that 
injecting pos-1 dsRNA, at a concentration just sufficient to produce a high degree of lethality 
in wild-type worms, produced high degrees of lethality in mes-2, -3, -4 and -6 loss-of-
function backgrounds.  Others have found previously that C. elegans dcr-1 is required for 
RNAi under some but not all conditions (17).  We wished to determine whether this is also 
true for mes-3, mes-4 and mes-6, and if so, under what conditions these genes are required for 
RNAi.  We tested whether the disparity between our results and Tabara et al. (20) could be 
attributed to differences in which mes alleles were tested, the specific dsRNAs assayed, or 
the concentration of dsRNA injected.  For mes-6, our results revealed that a null allele (see 
Figure 4.3 legend) was RNAi-deficient, but the weaker allele (37) that had been tested 
previously by Tabara et al. (20) was not (Figure 4.3C and 4.4A).  For mes-3 and mes-4, 
interestingly, an effect was found to be dependent on the concentration of dsRNA injected.  
Null alleles of mes-3 and mes-4 suppressed the effects of injecting typically-used (6, 19) 
concentrations of dsRNA, but, surprisingly, not the effects of injecting much lower 
concentrations of dsRNA (Figure 4.4B).  A similar, but weaker, concentration-dependence 
was found in the null mes-6 allele as well (Figure 4.4C).  We note that this result is not 
consistent with, and in fact is the inverse of, what one might expect from a hypomorphic 
allele of a gene required for RNAi.  This peculiar effect is also not specific to one mode of 
delivery of dsRNA, since introducing dsRNA by soaking worms in dsRNA, instead of 
injecting the dsRNA, produced similar results (Figure 4.4C).  These results suggest that low 
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concentrations of dsRNA elicit a response that is uniquely able to bypass a requirement for 
mes-3, mes-4 and to a lesser degree, mes-6, in RNAi.  MES-2, MES-3 and MES-6 are 
associated in a complex in C. elegans embryos (38); our results indicate that not all members 
of this complex are involved in RNAi.  Our results also suggest that a very low level of mes-
6 activity may be sufficient to function in RNAi, since only a null allele of mes-6 was RNAi-
deficient, and since loss of mes-2 function does not block RNAi (Figs 3B,C and 4C); loss of 
mes-2 function has been found previously to result in lower levels of MES-6 protein, levels 
similar to the weaker of the two mes-6 alleles we tested (37).  We conclude from our results 
that mes-3, mes-4 and mes-6 are required for RNAi under some but not all conditions.
    Our results have identified a total of five candidates for genes involved in the RNA 
interference mechanism in C. elegans -- gfl-1, zfp-1, mes-3, mes-4, and mes-6.  For three of 
these (mes-3, mes-4 and mes-6), null mutants were also RNAi-deficient.  Given the complete 
congruence of our RNAi-to-RNAi results with our results using mutants, we would predict 
that null mutants of the other two genes would also be RNAi-deficient; however, this remains 
to be determined.  We have not found any phenotypes other than RNAi-deficiency after 
RNAi of gfl-1 or zfp-1.  Since the RNA interference mechanism is silenced in these 
experiments, it is not clear whether a phenotype that would be seen in a loss-of-function 
mutant would result from RNAi of these genes; therefore, whether these genes have 
additional functions remains to be seen.
    All of the genes we have identified encode proteins that are predicted to associate with 
chromatin (36, 37, 42, S. Strome, pers. comm.).  RNAi in animals has been found to work 
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not at the level of DNA, but by degrading mRNA, and mRNA degradation can occur even in 
the absence of DNA (13).  How then might chromatin play a role in RNAi?  Our results to 
date can suggest only speculative models.  One possibility is that the role of chromatin is 
indirect -- that inactivation of genes such as the polycomb-group genes results in 
transcriptional misregulation that may block RNAi by saturating the RNAi mechanism with 
excess RNA, or by downregulating genes that encode components of the RNAi mechanism.  
We consider this unlikely, since RNAi can in fact occur in strong mes-3 and mes-4 mutants 
when dsRNAs are introduced at low concentration.  An alternative hypothesis that is 
consistent with current data is that introducing dsRNA in animal cells might result in both 
degrading mRNA and also recruiting a transcriptional silencing complex to the targeted 
locus.  Such a mechanism might conceivably be required for a penetrant RNAi effect, by 
further reducing a pool of endogenous mRNA through repressing transcription of specific 
loci.  In plants, introduction of dsRNA can cause both degradation of endogenous transcripts 
and silencing of the relevant locus (43), although silencing of the locus is thought to occur 
through DNA methylation (43, 44).  If dsRNA does induce gene silencing in C. elegans, it is 
unlikely that it occurs through DNA methylation, since little to no DNA methylation can be 
detected in C. elegans (45).  Based on our results, we have proposed that low concentrations 
of dsRNA might elicit a response that is uniquely able to bypass a requirement for mes-3, 
mes-4 and mes-6 in RNAi.  One mechanism that might be active only in the presence of low 
concentrations of dsRNA is amplification; it has been reported recently that dsRNAs can be 
amplified by siRNAs priming the production of new dsRNAs (46, 47).  It will be of interest 
to determine whether this amplification mechanism is active only when low concentrations of 
dsRNA are introduced, and if so, whether amplification of dsRNAs might bypass a 
75
requirement for mes-3, mes-4 and mes-6 in RNAi.  If our model, that dsRNA in animal cells 
might recruit a transcriptional silencing complex to the targeted locus, is correct, one might 
expect that amplification of dsRNAs could result in RNA interference sufficiently strong and 
lasting to bypass a requirement for transcriptional silencing.
    As with a standard genetic screen, an RNAi-based screen would be expected to have the 
potential to find both direct and indirect players in the process being studied.  Hence, like 
other proteins implicated in RNAi by genetics alone (18-21), how direct a role chromatin-
binding proteins play in RNAi remains to be determined.
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Fig 4.1.  Using pools of dsRNAs to identify genes that may be required for RNAi. 
(A) Ten pools injected in the pilot screen, and the embryonic lethality that resulted from each 
injection.  A pyramid of bars under each of the ten pool numbers represents the results from 
injecting a pool of eight dsRNAs (top row), two groups of four dsRNAs (second row), and then 
single dsRNAs (third row) into hermaphrodites.  Each bar is filled to a degree representing the 
percent embryonic lethality resulting from that injection (i.e., completely filled bars represent 
100% embryonic lethality).  Lethality was scored in embryos that were laid the day after 
injection by at least 10-15 adults that survived injection.  dsRNAs were reinjected in subgroups 
or as single dsRNAs for each pool that included a dsRNA expected to produce embryonic 
lethality (black dot), and/or was found to result in more than 20% embryonic lethality.  All 
other subgroups or single dsRNAs, which were not injected, are represented as empty gray 
bars.  As can be seen in the figure, ten dsRNAs expected to produce embryonic lethality based 
on their published mutant and/or RNAi phenotypes were present in seven of the ten pools.  Of 
these seven pools, only pool 2 failed to produce embryonic lethality.  An asterisk marks the 
M04B2.3 dsRNA, in pool 2.  The black bar next to M04B2.3 represents the glp-1 dsRNA.  
dsRNAs injected were the following, from left to right: pool 1 (C03C10.3, C25A1.8, EEED8.3, 
F56G4.3, F31F6.3, T05F1.2, C04F12.9, F33G12.4), pool 2 (F14B6.3, F40G12.11, 
Y11D7A.13, C50E3.13, C17E7.4, F02A9.6, M04B2.3, C16C8.16), pool 3 (C49F5.6, C38D9.2, 
D1009.2, C27C12.1, T22A3.7, B0416.4, F54D10.7, C01F6.4), pool 4 (C52D10.7, K07A1.2, 
F22B3.4, K04C1.5, F54D10.5, F45C12.7, T06E6.2, T11F8.3), pool 5 (ZK484.3, C27D9.1, 
C14B1.9, F52B5.2, F56G4.2, H02I12.1, F35C8.7, F19H6.4), pool 6 (F10G2.2, C25D7.6, 
K08E4.2, F40F8.9, T02C12.3, C32E8.8, C17E7.9, ZK632.1), pool 7 (F38E1.7, D2024.5, 
F20B6.7, R04D3.3, C29A12.3, ZK863.4, K05C4.6, C52D10.8), pool 8 (DY3.7, F17C11.10, 
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F28D1.2, K08A8.1, C50B6.3, T01G9.5, B0393.3, T20B12.8), pool 9 (F26G1.1, B0393.2, 
ZK154.5, F31E8.4, F21G4.2, ZC53.7, T04A8.7, C36B1.12), and pool 10 (W06E11.1, 
C27A2.6, K01G5.4, T04A8.8, F11C1.2, R10E4.4, T23B12.6, ZK154.7).  DY3.7 does not have 
a black dot despite being an essential gene (48) because others have shown that RNAi of 
DY3.7 does not produce a phenotype (49).  (B-F) Each graph represents the results from an 
experiment in which gravid adult hermaphrodites were injected, and a minimum of 10-15 
surviving adults were transferred to new plates periodically over the next 1-3 days, leaving the 
embryos laid between transfers on plates.  Embryonic lethality was scored at least 24 hours 
after the adults were removed from each plate.  Each dark gray box shows the percent of 
embryos that failed to hatch (y-axis) during a particular time window (x-axis).  Since each 
experiment in this figure includes an embryonic lethal dsRNA, low percent lethality reveals 
that a suppressor was coinjected.  All unlabeled axes are as in (B); vertical ticks mark lethality 
in 25% intervals and horizontal ticks mark time at 12 hour intervals.  (B) Lethality produced by 
a pool of eight dsRNAs that included glp-1 dsRNA and by glp-1 dsRNA alone.  (C) Lethality 
produced by glp-1 dsRNA coinjected with individual dsRNAs from the pool.  dsRNAs #2, 3, 4, 
5, 7 and 8 correspond to C. elegans genes C17E7.4, C16C8.16, F14B6.3, Y11D7A.13, 
C50E3.13, F40G12.11 respectively, derived from a collection of genes with germline-enriched 
transcripts (30). (D) Lethality produced by the pool with and without M04B2.3 dsRNA.  (E)
Lethality produced by five embryonic lethal dsRNAs each on their own and coinjected with 
M04B2.3 dsRNA.  (F) Lethality produced by mom-2 dsRNA injected alone or with mut-7, rde-
1, or control (unc-22 or gfp) dsRNAs.  
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Fig 4.2.  Protein Structure of  GFL-1 and ZFP-1 
(A) Diagram of C. elegans GFL-1 (M04B2.3), which has a predicted length of 211 amino acids 
(aa), and Human GAS41 (32, 33), which has a predicted length of 227 aa.  The two proteins 
share 50% amino acid identity over 200 aa. The acidic domain comprises 27% acidic residues 
over 60 aa for GAS41 and 25% acidic residues over 61 aa for GFL-1. (B) Diagram of C. 
elegans ZFP-1, which has a predicted length of 867 aa, and Human AF10, which has a 
predicted length of 1027 aa.  Percents amino acid identity in two regions are shown.  
PHD/LAP refers to plant homeodomain/leukemia-associated protein finger (50, 51).
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Fig 4.3. Testing candidate genes for roles in RNAi. .
All axes are as in Figure 4.1B; vertical ticks mark lethality in 25% intervals and horizontal 
ticks mark time at 12 hour intervals. (A) Lethality produced by mom-2 dsRNA or hmp-2 
dsRNA injected with or without zfp-1 dsRNA.  (B) Lethality produced by mom-2 alone (top 
row) or coinjected with dsRNAs corresponding to mes-2, -3, -4, and -6, or a control (unc-54) 
dsRNA.  (C) Lethality produced by injecting dsRNAs (mom-2, hmp-2 or par-2) in wild-type 
N2 worms or mes mutants (labeled along left side).  Asterisk indicates that for par-2, bn21ts
was tested at 25ºC in place of bn35.  ND: not determined.  mes-2(bn11), mes-3(bn35), mes-
4(bn23) and mes-6(bn64) (an allele with an early stop codon) each appear to be null alleles 
by immunostaining (36), (37), (52), Y. Fong and S. Strome, personal communication), and 
mes-6(bn66) (a missense allele) was found to produce small amounts of MES-6 protein by 
immunostaining (37).  RNAi-deficient phenotypes in mes-3, mes-4 and mes-6 mutants are 
unlikely to be due to genetic background, since these strains were outcrossed multiple times 
during construction (39), and since our results with mutants are consistent with our RNAi-to-
RNAi results above. 
86
87
Fig 4.4  mes-3, mes-4, and mes-6 are required for RNAi under certain conditions. 
Effectiveness of RNAi is shown in (A) mes-6(bn64) and N2 tested by injection, (B) mes-
3(bn35), mes-4(bn23) and N2 tested by injection (mes-3 and N2 control carried out 
simultaneously are shown in gray) (mom-2 dsRNA was also injected in mes-3(bn35), with 
similar results; not shown), and (C) mes-2(bn11), mes-3(bn35), mes-4 (bn23), mes-6(bn64) 
and N2 tested by soaking worms in 100ng/µl or 800ng/µl pos-1 dsRNA.  For injection 
experiments, numbers reflect lethality of embryos laid on the day after injection (from 15-24 
hours to 44-59 hours post-injection).  For soaking experiments, numbers (ave +/- SD for a 
minimum of 3 trials) reflect lethality of embryos laid between 38 and 62 hours after the end 
of soaking.  All of the mes alleles used here appear to be null alleles by immunostaining (36, 
37, 52, Y. Fong and S. Strome, personal communication).
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CHAPTER V:  GENETIC REQUIREMENTS FOR RNAI
INTRODUCTION
    RNA-mediated interference (RNAi) is a conserved process that directs sequence-specific 
degradation of mRNAs (1).  RNAi and similar phenomena in other organisms are believed to 
be part of an ancient pathway aimed to prevent both the invasion of foreign nucleic acids into 
the genome and the expression of aberrant RNAs (2, 3, 49, 5, 6).  Genes required for RNAi 
have also been implicated in developmental processes in both plants and animals, suggesting 
that RNAi may play a more extensive role in regulating gene expression (7, 8, 9, 10, 11, 12). 
However, the mechanics of RNAi are only partially elucidated.
    RNAi has also become a widely used tool to study gene function in a number of organisms 
and has been used in a number of large-scale loss-of-function screens (13, 14). RNAi-based 
methods for identifying genes required for RNAi have also been developed (15, 16). Using 
RNAi to identify genes required for RNAi has the benefit over conventional forward genetic 
screens in that it forgoes the need to clone mutant the genes identified, which may take 
months or years to complete.  To date, RNAi-based screens aimed at identifying new genes 
required for RNAi have employed the use of feeding C. elegans E. coli which express 
double-stranded RNA (dsRNA) to induce an RNAi response (16, 17, 18).  Performing RNAi 
by feeding has many advantages:  Feeding is far less laborious than microinjection and hence 
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is convenient when performing RNAi on a large number of worms or when testing a large 
number of different genes.  However, feeding animals with bacteria expressing dsRNA is not 
always completely effective, as loss of function phenotypes for a number of genes can be 
missed (19, 20).  
    To identify new genes required for RNA interference in C. elegans, we performed a 
candidate-based screen using RNA interference.  We co-injected candidate dsRNAs together 
with a dsRNA targeting an essential gene, and those candidate dsRNAs that inhibited 
embryonic lethality were considered further.  We then retest these using mutant animals to 
verify a genetic requirement in RNAi.  Our approach is unique, in that, it employs 
microinjection to screen.  Feeding and microinjection of dsRNAs can sometimes produce 
different results (15). These differences might reflect differences in the levels of dsRNA 
introduced by the respective methods and may well reflect differences in the duration or 
exposure to the dsRNA trigger. 
    Using mutant animals, we were able to validate roles for 14 genes in RNAi.  11 of these 
genes encode protein products known to function in the nucleus.  We have further 
characterized the role of one of these proteins, RHA-1, in RNAi.
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MATERIALS AND METHODS
Worm strains 
C. elegans was maintained as in (Brenner 1974).  Strains and alleles used were Bristol Strain 
N2 (wild type), rha-1(tm329), rde-1(ne219), rde-1(ne300),rde-2(ne221), rde-3(ne298), rde-
4(ne301), mut-7(pk204), mut-14(pk738), unc-22(r765::Tc4), mut-7(pk204);unc-
22(r765::Tc4), and rha-1(tm329);unc-22(r765Tc4), hpl-1(ok1060), hpl-1(tm1624), lin-
13(ok838), lin-13(n387), lin-13(n770), chd-3(eh4), tam-1(cc567), tam-1(sy272), cec-
1(ok1063), lin-59(sa489), lin-59(cxTi9220), mys-1(tm1628), lim-6(nr2073), gap-2(tm748), 
rnf-5(tm784), hil-1(gk228), lim-4(ky403), gei-7(ok531), unc-119(e2498::Tc1); wIs51, jcis1, 
rha-1(tm329); ruIs57, mut-7(pk204);ruIS57
Primer design and dsRNA synthesis
 PCR was used to generate templates that were then used for dsRNA synthesis as described 
in (15).
Microinjection
The co-injection assay was performed by co-injecting 30 ng/µl of target dsRNA (for 
example, mom-2) together with 100ng/µl of test dsRNA (for example, dcr-1) into either the 
gut or gonad of adult wild-type hermaphrodites. For each experiment in Figures 5.4, 5.5, 5.6, 
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and 5.12, 150-300ng/µl dsRNA was injected.  siRNAs were injected at 300ng/µL.
unc-22 reversion assay
Activity of transposition was determined by the phenotypic reversion of transposon alleles of 
the unc-22 (r765::Tc4) gene. The number of wild-type revertants in the progeny of a given 
generation was used to determine the transposition frequency.
Seam cell assays
Seam cell fusions were visualized using jcIs1 transgenic animals.   Animals containing this 
transgene were injected with 300ng/µL dsRNA targeting rha-1 or dcr-1, and seam cell 
fusions were observed in the adult progeny of inject animals.  Determination of seam cell 
numbers was achieved by using SCM::GFP animals, which contain a nuclear localized GFP 
marker specifically expressed in the seam cells. 
RESULTS AND DISCUSSION
    An RNA interference-based strategy used to identify new genes required for RNAi
We have previously reported that the co-injection of double-stranded RNAs (dsRNAs) 
targeting an essential gene together with a candidate dsRNA can be used to identify genes 
having roles in RNA interference (15).  We have extended this method to test fifty-six 
candidate genes for potential roles in RNAi. In this study, we co-injected each candidate 
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dsRNA along with a dsRNA that targeted an essential transcript, such as C. elegans mom-2, a 
member of the Wnt signaling family, or glp-1, a member of the Notch family, whose 
functions are both required early in C. elegans development. The dsRNAs were injected 
directly into the adult hermaphrodites and viability of the progeny was scored. (Figure 5.1).
    Candidates were selected based on sequence and include genes whose products we 
reasoned as likely to participate in RNAi, such as predicted RNAses, helicases, DNA/RNA 
binding proteins, and RNA processing proteins. In addition to these genes, regulators of 
transcription, translation, protein stability and chromatin modifiers were also selected under 
the hypothesis that RNAi may act at several steps to restrict gene expression (Table 5.1). The 
C. elegans genome is completely sequenced, thus facilitating candidate selection (C. elegans
Sequencing Consortium 1998).  Of our fifty-six candidates, we have found 36 dsRNAs 
capable of suppressing the lethality associated with injecting dsRNAs targeting an essential 
transcript (Figure 5.2). 
    Injection of dsRNA targeting mom-2 alone produced, on average, 90% lethality in the 
progeny of injected animals. Those candidates whose average percent lethality fell under 
60% were considered as positives for further study. It is important to note that genes required 
for both RNAi and viability may not be recovered in this screen, as loss of function of these 
genes will also result in embryonic lethality in the progeny. We also injected 14 dsRNAs as 
negative controls. which all failed to suppress mom-2 mediated embryonic lethality, 
suggesting a low rate of false positives.  However, we were surprised by the high number of 
suppressors obtained from this screen and therefore tested these candidates further, in a 
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secondary screen, by determining whether available loss of function mutations of some of 
these genes also resulted in RNAi-deficient animals. 
Loss of function mutants confirm the requirement of some genes for RNA interference:
    Using mutant animals, we tested 16 genes for potential roles in RNAi by determining 
whether loss of function mutants are also RNAi-deficient. Candidates whose mutants 
reproducibly suppressed the lethality for at least two essential gene targets in independent 
experiments were considered bona fide genes required for RNAi.  Under these criteria we 
have confirmed the identification of nine new genes required for RNAi (Table 5.2).  
Therefore, we were able to validate slightly more than half (56%) of the co-injection 
candidates tested using animals harboring mutations in these genes.  The 44% that could not 
be validated suggests that introducing multiple dsRNAs may produce a significant rate of 
false positives.  Previous studies have used RNAi to identify genes believed to be required 
for RNAi, sometimes without testing genetic mutants (16, 17, 18).  Based on our results, we 
suggest that introducing multiple dsRNAs can be used as an effective method to enrich for 
new genes required for RNAi, but that testing candidates further by using mutant animals is a 
necessary step in confirming genetic requirements for RNAi. 
The identification of additional genes required for RNAi:
    We next asked whether we could identify additional genes required for RNAi by testing 
for RNAi deficiency in animals mutant for genes known to interact either genetically or 
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biochemically with the genes identified in this study. In the published literature and protein 
interaction databases, we identified interactors with available mutant animals which we 
subsequently tested for sensitivity to RNAi by targeting an essential gene and scoring for 
viability in the progeny. As before, candidates that reproducibly proved positive for at least 
two different gene targets in independent experiments we considered as bona fide genes 
required for RNAi. Under these criteria, we have identified five additional genes required for 
RNAi (Table 5.2). Our study has therefore identified a total of 14 new genes required for 
RNAi.  Based on the sequences of these genes, the new RNAi components fall into several 
distinct functional classes. 
Functional classes of the validated genes required for RNAi:
   Of the 14 genes we have identified in C. elegans as having roles in RNAi, 11 encode 
protein products known to function in the nucleus.  Our data, and that of others (15, 16, 21), 
suggests that dsRNA may inhibit gene expression in animals as it does in plants and fungi 
(22, 23, 24, 25, 26, 27), possibly through the ordered remodeling of chromatin. 
Genes involved in chromatin structure and modification:
    Different combinations of histone modifications, in the form of a ‘histone code’, direct 
chromatin-binding proteins to induce chromatin remodeling at specific loci and thereby 
regulate gene expression (28, 29).  While much has been elucidated, a complete 
understanding of how specific histone modifications translate into altered gene expression 
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remains to be determined.  In this study we have identified six chromatin-binding proteins 
required for RNAi, hpl-1, cec-1, lin-59, chd-3, mys-1, and hil- 1.
    HPL-1 is one of two heterochromatin proteins in C. elegans and is partially redundant with 
C. elegans HPL-2 for the development of a functional germline and vulva (30). hpl-1 was 
also isolated from a screen for genes required for cosuppression, an RNAi-related silencing 
process (31). Injection of mom-2, nmy-2, par-2, and ama-1 dsRNAs produced highly 
penetrant embryonic lethality in the progeny of wild-type animals, while RNAi of these 
genes was strongly suppressed in hpl-1 mutant animals (Table 5.2).  It is of note that C. 
elegans HPL-1 and its homologs in other organisms, such as yeast and Drosophila, are
required for a similar silencing phenomenon, transcriptional gene silencing or TGS (26, 32, 
33, 34). 
    Since HPL-1 acts to support the activity of HPL-2 in promoting germline function (30), we 
next asked whether HPL-2 might also play a role in RNAi.  Using an hpl-2 deletion mutant, 
we injected dsRNAs targeting mom-2 and found highly penetrant embryonic lethality, thus 
we found no evidence of a requirement for hpl-2 in RNAi (data not shown). Interestingly, 
however, a mutation in hpl-2 was shown to greatly reduce TGS and confer a slight 
hypersensitivity to RNAi in other assays (32, 35).
    CEC-1 is a chromodomain protein, containing a conserved motif originally identified as a 
region of homology between Polycomb and the heterochromatin protein HP1 in Drosophila
(36). Injection of mom-2, nmy-2, and ama-1 dsRNAs produced highly penetrant embryonic 
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lethality in the progeny of wild-type animals, while RNAi of these genes was strongly 
suppressed in cec-1 mutant animals (Table 5.2).  With the exception of the chromodomain, 
CEC-1 shares no other structural features with other chromodomain-containing proteins, in 
particular, CEC-1 does not contain a recognizable chromo shadow domain or a DNA binding 
motif.  This suggests that CEC-1 may possess specialized functions distinct from other 
chromodomain containing proteins (36, 37)).
    LIN-59 was originally identified in a screen for genes affecting C. elegans hindgut 
development and was shown to regulate gene expression by directing the remodeling of 
chromatin (38). LIN-59 is most similar to the Drosophila trithorax group chromatin-
modifying protein ASH1, which modifies chromatin to maintain gene activity (39, 40). 
Injection of mom-2 and nmy-2 dsRNAs produced highly penetrant embryonic lethality in the 
progeny of wild-type animals, while RNAi of these genes was strongly suppressed in lin-59 
mutant animals (Table 5.2). 
    CHD-3 is one of two C elegans Mi-2 homologues, a component of the C. elegans
nucleosome remodeling and histone deacetylase (NuRD) complex that is important for 
transcriptional regulation (41, 42). Injection of nmy-2 and par-3 dsRNAs produced highly 
penetrant embryonic lethality in the progeny of wild-type animals while RNAi of these genes 
was strongly suppressed in chd-3 mutant animals (Table 5.2). The roles of the NuRD 
complex in the regulation of development are incompletely understood, however, the two C. 
elegans Mi-2 homologs have been shown to have partially redundant functions during 
development of the vulva to negatively regulate Ras signaling (42, 43).  
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    MYS-1 is a histone acetyltransferase belonging to the MYST family and was recently 
shown to negatively regulate Ras signaling in vulva development (44).  Injection of mom-2 
and nmy-2 dsRNAs produced highly penetrant embryonic lethality in the progeny of wild-
type animals while RNAi of these genes was strongly suppressed in mys-1 mutant animals 
(Table 5.2).  Acetylation of histones is associated with increases in gene expression (45) 
suggesting that MYS-1 might act as a transcriptional activator in response to RNAi. 
    HIL-1 is a linker histone (H1) protein. Linker histones can act to stabilize chromatin 
structure and protect DNA from nuclease activity (46).  hil-1 was identified in a comparative 
expression screen as having up-regulated mRNA levels in response to starvation/dauer arrest 
(47). Injection of mom-2 and ama-1 dsRNAs produced highly penetrant embryonic lethality 
in the progeny of wild-type animals, while RNAi of these genes was strongly suppressed in 
hil-1 mutant animals (Table 5.2). 
SynMuv pathway genes required for RNAi:
    The synthetic multivulva (SynMuv) genes negatively regulate vulval induction. The 
SynMuv genes fall into two classes, A and B. Loss-of-function mutations in both a class A 
gene and a class B gene result in a multivulva phenotype due to increased Ras signaling, 
revealing two redundant pathways that cooperate to antagonize vulval cell fates (48).  It has 
been reported that Rb (a SynMuv B gene) can also antagonize Ras signaling during vulva 
development (4) and the inactivation of some Rb pathway components also results in RNAi 
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hypersensitivity (35).  In this study, we have identified two genes in the SynMuv B pathway 
that are required for RNAi.  
    LIN-13, first identified in a multivulva (Muv) screen, is a nuclear protein containing 
multiple Zinc-fingers and functions as a transcriptional regulator. Injection of mom-2, nmy-2, 
par-2, par-3, and ama-1 dsRNAs produced highly penetrant embryonic lethality in the 
progeny of wild-type animals, while RNAi of these genes was strongly suppressed in lin-13 
mutant animals (Table 5.2).  A recent study reported, at least under certain conditions, an 
enhanced RNAi phenotype of some SynMuv B pathway mutants, including lin-13 and other 
factors that interact with C. elegans Rb (35, 50). 
    A second gene in the SynMuvB pathway is tam-1, which was originally identified in a 
screen for factors that negatively modulate repeat-associated silencing in C. elegans, a form 
of gene silencing operative in the germline that inhibits expression from arrays containing 
highly repetitive DNA sequences (51). TAM-1 is a RING finger protein containing B-box 
motifs, a motif found in some nuclear proteins (52). Injection of mom-2, nmy-2, and par-3 
produced highly penetrant embryonic lethality in the progeny of wild-type animals, while 
RNAi of these genes was strongly suppressed in tam-1 mutant animals (Table 5.2). 
Other genes required for RNAi:
    We have identified several other genes whose sequences suggest to us no singular 
prediction of how they might function in RNAi.  Their identities are described below:
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C. elegans gap-2 encodes a novel Ras-GTPase activating protein (Ras-GAP)  (53). 
Injection of mom-2 and ama-1 dsRNAs produced highly penetrant embryonic lethality in the 
progeny of wild-type animals, while RNAi of these genes was strongly suppressed in gap-2 
mutant animals (Table 5.2).  Ras-GAPs are predicted to function as negative regulators of 
Ras function (54).  So far, only two C. elegans RasGAPs have been identified.  The C. 
elegans RasGAP gap-1 was isolated in a screen for inhibitors of Ras signaling (55), and gap-
2 was isolated in a yeast complementation screen. gap-2 is encoded by several distinct splice 
variants and has reported functions as a negative regulator of Ras signaling during larval 
development (53). 
RNF-5 is a C3HC4 RING finger protein.  The RING finger motif exists in E3 ligases of 
the ubiquitin pathway (56, 57, 58).  In C. elegans, RNF-5 reportedly functions as an E3 
ligase (58). Injection of mom-2 and nmy-2 dsRNAs produced highly penetrant embryonic 
lethality in the progeny of wild-type animals, while RNAi of these genes was  strongly 
suppressed in rnf-5 mutant animals (Table 5.2).
GEI-7 is a key enzyme in the glyoxylate pathway, which helps to convert fatty acids into 
sugars. GEI-7 is reportedly induced by starvation in all developmental stages of C. elegans
and is likely to function in a starvation response system (59, 60). Injection of mom-2 and par-
3 dsRNAs produced highly penetrant embryonic lethality in the progeny of wild-type 
animals, while RNAi of these genes was strongly suppressed in gei-7 mutant animals (Table 
5.2). 
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LIM-4 and LIM-6 are proteins containing a DNA-binding homeodomain and two Zinc-
finger like LIM domains, a domain that mediates protein–protein interactions (61). In C. 
elegans, these proteins act as transcription factors and are required for differentiation of 
chemosensory neurons (62, 63).  Injection of mom-2 dsRNAs produced highly penetrant 
embryonic lethality in the progeny of wild-type animals, while RNAi of mom-2 was strongly 
suppressed in lim-4 mutant animals (Table 5.2). Likewise, mom-2, nmy-2 and par-2 RNAi 
was strongly suppressed in lim-6 mutant animals (Table 5.2).  
A conserved RNA Helicase with double-stranded RNA binding domains is required for 
RNAi in C. elegans:
    Our co-injection screen also identified C. elegans RHA-1, which contains a conserved 
helicase domain, two dsRNA binding domains (dsRBD) and a non-canonical nuclear 
localization sequence (Figure 5.3).  C. elegans RHA-1 is homologous to Drosophila maleless 
(mle) and to RNA Helicase A in humans. These proteins are known to function in the 
nucleus (64, 65). The mle gene product influences chromatin structure and plays a critical 
role in dosage compensation by hyperactivating the male’s single X chromosome. Mle has 
also been shown to possess both RNA and DNA helicase activities, ATPase activity, and 
RNA / DNA binding activities (65).  The human homolog, RNA helicase A, is also known to 
function in the nucleus and is competent to unwind dsRNA (64).
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Further characterization of C. elegans RHA-1:
    In this study and a previous study, we identified several nuclear proteins having roles in 
RNAi (15) yet very little is known as to the nature of how RNAi functions in the nucleus in 
animals (66, 67, 68, 69).  We therefore sought to investigate in more detail the role of one 
putative nuclear protein, RHA-1, in C. elegans. A deletion mutant in rha-1 was obtained 
from the C. elegans Knockout Consortium. This deletion, rha-1(tm329) removes 1059 base-
pairs of DNA early in the sequence, creating a frameshift that produces a premature stop 
(Figure 5.3). We have found that rha-1(tm329) animals are resistant to RNAi irrespective of 
the method of dsRNA delivery: Injection, feeding, or soaking of different dsRNAs targeting 
essential genes.  We injected, fed, or soaked various dsRNAs into wild-type and rha-
1(tm329) mutant animals.  In each case, we found highly penetrant embryonic lethality in the 
progeny of wild-type animals while RNAi was strongly suppressed in rha-1 mutant animals 
(Figure 5.4).  Our results are consistent with recently reported results of others who have 
shown rha-1(tm329) to be resistant to both pos-1 and par-1 RNAi (31).
    To test if rha-1(tm329) represents a dominant mutation, we injected dsRNAs targeting 
mom-2 into wild-type, rha-1 homozygous mutants, and animals heterozygous for rha-1 (rha-
1/+).  Injection of dsRNAs targeting mom-2 produced highly penetrant embryonic lethality in 
the progeny of wild-type and rha-1/+ animals while RNAi was strongly suppressed in rha-1 
homozygous mutant animals (Figure 5.5).  We originally identified rha-1 using dsRNAs 
against germline-expressed transcripts, prompting us to ask if rha-1 is also required for RNAi 
in the soma. We used two tests to silence somatic gene expression.  First, we injected 
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dsRNAs targeting two somatic transcripts, unc-54 and unc-120 into wild-type and mutant 
animals and scored for an Unc (uncoordinated) phenotype in their progeny.  Injection of
dsRNAs targeting these somatic transcripts produced highly penetrant uncoordinated animals 
in the progeny of both wild-type and rha-1 mutant animals (Figure 5.6A and 5.6B).  As an 
additional test, we also examined the consequence of losing RHA-1 function on the ability of 
GFP(RNAi) to silence gene expression of a GFP fusion protein expressed zygotically.  To 
this end, we co-injected dsRNAs targeting rha-1 together with a dsRNA targeting GFP into 
the hermaphrodite gonad of a wild-type strain carrying an ELT-2::GFP transgenic array and 
scored animals for GFP expression.  Injecting GFP dsRNA alone into this strain effectively 
silenced ELT-2::GFP expression, while the co-injection of dsRNA targeting dcr-1, which is 
required for RNAi, along with dsGFP failed to suppress GFP expression. However, the co-
injection of dsRNA targeting rha-1 together with dsGFP effectively silenced GFP expression 
(Figure 5.6C).  We propose that rha-1 is required specifically for RNAi to function in the 
germline, as RNAi to somatic genes were unaffected.   A similar effect was previously 
observed with mut-7(pk204), which primarily affects RNAi of maternally expressed genes 
(70). This suggests the existence of a germline-specific RNAi pathway, in which mut-7 and 
rha-1 may function.
RHA-1 may belong to a unique class of proteins that function in RNAi:
    Mutations in components of the RNAi machinery can be separated into two functional 
classes: Class I components are required for RNAi, while mutants in Class II components are 
required for RNAi and in addition, mutants possess activity which leads to higher incidences 
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of chromosomal non-disjunctions, defects in germline silencing, and higher transposition 
rates (70, 71, 72).  To better understand the role of RHA-1 in RNAi, we assayed rha-
1(tm329) animals for these phenotypes. We analyzed the frequency of males as a read-out of 
non-disjunctions, in populations of wild-type, rde-2, and rha-1 mutant animals.  We found 
that rha-1 has a high incidence of males (Him), comparable to that found in animals with 
mutations in rde-2 (Figure 5.7A). Other Class II RNAi components, such as mut-7 and rde-3, 
have similar phenotypes (70, 71).
    Repetitive multicopy transgenes are silenced in the C. elegans germline but not in the 
soma (73).  To test whether RHA-1 may also play a role in germline silencing, we asked if 
the loss of rha-1 could lead to de-silencing of a silenced repetitive transgene in the germline.  
rha-1(tm329) animals were crossed into a silenced -tubulin::GFP strain, and expression of 
the transgene was monitored over several generations.  We found that the loss of rha-1 leads 
to de-silencing of the transgene in a temperature-sensitive manner (Table 5.3). Consistent 
with our data, rha-1 has recently been shown to be required for cosuppression, a related 
RNA-mediated silencing phenomenon, and also for transcriptional germline silencing (31, 
74).
    We next asked whether loss of rha-1 resulted in a higher level of transposition. We used a 
transposition-deficient strain that carries a transposon insertion (Tc4) disrupting unc-22. Loss 
of unc-22 function produces animals with abnormal muscle structures apparent under the 
dissecting scope by twitching (75). Transposition of Tc4 can lead to revertants showing a 
wild-type phenotype.  We placed this strain into an rha-1(tm329) background and scored the 
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percentage of wild-type revertants.  We found that reversion frequencies of rha-1;unc-
22(Tc4) double mutants were the same as in wild-type, suggesting that rha-1 does not play a 
role in transposon mobilization (Figure 5.7B). Thus, rha-1 may define a third class of RNAi 
components whose activities can be uncoupled, having roles in chromosome segregation and 
transgene silencing, but not in the repression of mobile elements. 
    The RHA-1 sequence includes multiple predicted nuclear localization signals (76).  To 
determine whether RHA-1 has the potential to be a nuclear protein, we created a rescuing 
RHA-1::GFP construct that contains the entire coding sequence of RHA-1 and 1.4 kilobases 
of upstream sequences.  This construct was integrated by gamma irradiation, and two stable 
lines were recovered. These lines showed nuclear-enriched GFP localization as well as some 
cytoplasmic GFP localization. 
    RHA-1::GFP expression is found in somatic tissues such as the muscle and hypodermis, 
while no visible expression was observed in the germline (Figure 5.8). RHA-1’s RNAi 
phenotype is germline specific, and in situ hybridization experiments show rha-1 mRNA 
expressed exclusively in the germline (77).  As our construct rescues the RNAi defect in rha-
1(tm329) animals, a likely explanation could be that the relevant cells express very low levels 
of RHA-1, which cannot be detected by our methods, and the somatic expression observed is 
a result of RHA-1 over-expression.  In addition, our over-expression experiments suggests 
that a delicate balance of RHA-1 expression is required for fertility, as both over-expression 
and loss of function of RHA-1 can lead to sterility (Table 5.4).  Based on our overexpression 
experiments, we conclude that RHA-1 can localize to the nucleus. 
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RHA-1 may act downstream of siRNAs:
    To better understand where RHA-1 acts in the RNAi pathway, we asked if the introduction 
of siRNAs in rha-1 mutant animals could bypass the requirement for RHA-1 in RNAi.  
During RNAi, long dsRNAs are cleaved into siRNAs by the RNAse III enzyme Dicer.  Thus, 
by injecting RNAi deficient mutant animals with siRNAs targeting essential transcripts, such 
as mom-2, and assaying for lethality, we can determine whether a gene functions upstream or 
downstream of Dicer and siRNA production.  Injections of siRNAs were made in various 
RNAi mutant backgrounds, including rha-1(tm329).  We found that siRNAs could not 
bypass the requirement for RHA-1, suggesting that RHA-1 is required  downstream of 
siRNA production (Figure 5.9). Recently it has been shown that rha-1 is required for 
transcriptional silencing in the gonad and that loss of rha-1 leads to defects in histone 
modifications, consistent with a role downstream of siRNA production (74).   Interestingly, 
siRNAs worked considerably better in an rde-3 mutant background suggesting that RDE-3, a 
nucleotidyltransferase, may negatively regulate siRNA activity.
Developmental defects in rha-1 mutant animals:
    A number of RNAi components have been shown to have roles in development, such as 
dcr-1 and ego-1. We scored rha-1(tm329) animals for developmental defects and noticed that 
rha-1(tm329) hermaphrodites had more than a 50% reduction in brood-size compared to that 
of wild-type animals, and that rha-1(tm329) males mated poorly (Figure 5.10A and 5.10B). 
Developmental defects in rha-1(tm329) animals have also been reported independently and 
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are in agreement with our findings (74, 78).
RHA-1 does not regulate the heterochronic pathway in C. elegans:
    In C. elegans, the lin-4 and let-7  genes promote transitions from earlier to later larval 
stages and, thus, mutations in these genes cause reiteration of early cell fates at later stages   
Such genes have been termed heterochronic genes, and the short RNAs encoded by some of 
these genes are called small temporal RNAs (stRNAs) (64, 79).  Loss-of-function mutations 
in let-7  result in a failure of larval seam cells in the hypodermis to progress to the adult-
specific program of terminal differentiation, indicated by the production of the adult-specific 
alae and, instead, the cells repeat the early larval type of divisions. These reiterated divisions 
contribute to a failure to form the adult specific alae.
    It has been previously reported that the developmental defects found in dcr-1(RNAi) 
animals also result from temporal misspecifications in the seam cell lineages and that Dicer is 
not only required for RNAi, but also to process the lin-4 and let-7 precursor RNAs  (8, 17). 
To investigate whether rha-1 regulates stRNAs, we analyzed seam cell divisions in worms 
exposed to rha-1 dsRNA. Normally, some of the ten seam cells present at hatching divide to 
generate 16 cells during the second larval stage. Although these 16 cells divide at the 
succeeding third and fourth larval stages, only one daughter cell maintains the seam cell fate 
(80), and the total number of seam cells in the adult is 16. To aid in the observation of seam 
cell divisions, we utilized a transgenic strain that drives GFP expression specifically in the 
seam cell nuclei. While we did find defects in seam cell numbers in animals injected with 
108
dsRNA targeting dcr-1, we found no obvious defects in rha-1(tm329) (Figure 5.11A).   In 
addition, we examined alae formation under DIC optics in animals exposed to dsRNAs 
targeting either rha-1 or dcr-1 and found that the loss of rha-1 had no effect on alae 
formation, while dcr-1(RNAi) resulted in defects in alae structure (Figure 5.11B).  
    A previous study reported that seam cells in dcr-1(RNAi) animals failed to fuse (17).  To 
assay seam cell fusion defects in rha-1 animals, we injected dsRNA targeting rha-1 or dcr-1 
into a strain expressing JAM-1::GFP, which outlines the seam cells. dcr-1 (RNAi) in this 
background led to seam cells fusion defects, while fusions were unaffected in rha-1(RNAi) 
animals (Figure 5.11C).  Together, our data suggest that RHA-1 does not have an essential 
function in regulating stRNAs.
rha-1(tm329) shows sensitivity to par-2(RNAi):
    We have shown that RHA-1 is required specifically to silence germline expression during 
RNAi, however we noticed that rha-1(tm329) animals were sensitive to RNAi of the 
germline expressed transcript, par-2 (Table 5.2).  We considered the possibility that the 
particular dsRNA used to target par-2 might somehow account for the lack of suppression in 
rha-1(tm329) animals.  To test this, we generated dsRNA corresponding to a separate region 
of the par-2 gene and injected this dsRNA into wild-type and rha-1(tm329) mutant animals 
(Figure 5.12A).  We found that this produced highly penetrant embryonic lethality in rha-
1(tm329) animals.  We next asked whether other DEAD/H box helicases required for RNAi 
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behaved similarly.  We tested par-2(RNAi) sensitivity in rha-1(tm329) and mut-14(pk738) 
mutant animals (81).  We also tested other known genes required for RNAi, rde-1,rde-2, rde-
3, and mut-7.  We show that, except for rha-1(tm329), all RNAi mutants tested were 
completely resistant to par-2(RNAi) (Figure 5.12B).  Thus, while we have shown that rha-1 
is required specifically in the germline, our data suggests that rha-1 may not be required to 
silence all germline targets.  This result raises the possibility that some components of the 
RNAi machinery function in RNAi of specific classes of target genes.
Other RNAi components may also show target specificity:
    We show that while rha-1 is required for RNAi of several germline expressed genes it is 
not required for all targets.  Additionally, we found this to be true for hpl-1, chd-3, cec-1, 
gap-2, rnf-5, hil-1, lim-4, gei-7, and, tam-1 (Table 2).  These results suggest a level of target 
specificity among certain genes required for RNAi.  We therefore propose that there may 
exist protein complexes that function in RNAi only of certain classes of target genes as part 
of an RNAi regulatory pathway that provide specificity for gene silencing.
CONCLUSIONS
    RNA-mediated gene silencing has become an important tool to analyze gene function in 
many organisms.  Moreover, the ability to readily silence specific genes holds promise in 
designing effective therapies to combat a range of illnesses.  The continued identification of 
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genes required for RNAi is an important step toward understanding of the mechanisms of 
RNAi .
    Because most protein components of RNAi, including Dicer, assemble and function in the 
cytoplasm, the relationship between transcriptional gene silencing and RNAi has not yet been 
clearly established in C. elegans.  We can not rule out the possibility that some of genes 
identified may not have direct roles in RNAi, for instance, not as active participants in 
silencing, but rather as regulators of RNAi or whose loss of function may misregulate RNAi, 
in particular, or globaly either by down-regulating genes that encode components of the 
RNAi mechanism or by saturating the RNAi mechanism with excess RNAs.  However, some 
of the gene products identified have homologs that play similar roles in silencing phenomena 
in other organisms.  Overall, the new genes we have identified provide evidence for a 
relationship between transcriptional gene silencing and RNAi in C. elegans worthy of further 
investigation. 
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Figure 5.1.-  RNAi co-injection assay for identifying genes required for RNAi.
 (A) dsRNA targeting an essential gene such as mom-2 is injected into hermaphrodite gonads, 
and the worms are placed onto an agar plate containing OP50 E. coli  bacteria.  The injected 
worms are transfered every 12 hours ,and the eggs are scored for viability.  Since mom-2 is 
an essential gene, knocking down its function by RNAi should produce a high percent 
lethality in the progeny, represented here by a large number of unhatched eggs on the plates. 
(B) Co-injecting mom-2 dsRNAs with a dsRNA targeting a gene required for RNAi, such as 
dcr-1, suppresses the lethality associated with mom-2(RNAi), represented here by the large 
numbers of worms that have hatched on the plates. (C) Our screen involves co-injecting 
dsRNA targeting mom-2 together with each candidate dsRNA. Positive candidates are those 
that result in viable progeny that have escaped the lethality associated with mom-2(RNAi).
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Figure 5.2. Results from the candidate screen. 
dsRNA targeting an essential gene, mom-2, was injected either alone or in combination with 
a candidate dsRNA into either the gut or gonad of adult wild-type hermaphrodites. Embryos 
laid 24-50 hours post-injection were scored for viability. Candidates are sorted from lowest 
percent lethality to highest. Those candidates whose average percent lethality was under 60% 
(dotted line) were considered positive for suppression of RNAi. dsRNAs in figure: mom-2 
alone, mom-2 dsRNA injected with six positive controls (rde-1 mut-7 dcr-1 mes-4, mes-3, 
rde-2),  and mom-2 dsRNA injected with 14 negative controls (unc-44, unc-54, rol-6, bli-3, 
C33H5.9, T28F2.5, dpy-11, F25B4.9, apt-4, gfp, ZK856.8, rps-26, C14C10.2, dpy-3), and 
mom-2 dsRNA injected with 56 candidates (T20G5.11, lim-6, T26G10.,1 lin-1,3 lin-59, hil-
5, his-2,4 tam-,1 hil-,3 C05C10.2, hil-4, puf-8, pab-3, C50B8.1, hpl-1, chd-3, rha-1, 
K02F3.1, C44H9.4, puf-9, K02F3.12, F48E8.6, cec-1, mys-1, T02C1.1, K09F5.5, rcq-5, 
C54H2.3 ,H03G16.3, ZK669.2, T05E8.3, lin-49, hil-6, F37C12.13, C34B7.1, C06E1.10, crn-
5, F26E4.13, W08D2.7, Y113G7B.14, him-6, B0564.1, F15D4.1, B0041.7, F56D2.6, 
F01G4.3, C24H11.6, crn-3, F55A4.4, K03D10.3, dis-3, ZK1098.3, psa-4, smn-1, R07E5.3, 
wrn-1).  Error bars represent standard deviations.
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Figure 5.3.- Predicted protein structure of C. elegans RHA-1 and its Drosophila and 
Human homologs. 
These proteins contain two double-stranded RNA binding domains (dsRBD) and two 
helicase motifs.  rha-1 (tm329) is a predicted null and was obtained from the C. elegans
Knockout Consortium The deletion in rha-1 (tm329) removes 1059bp very early in the 
sequence and creates a frameshift that produces a premature stop. 
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Figure 5.4.- rha-1(tm329) is resistant to RNAi. 
(A) Lethality induced by mom-2 (RNAi) by injection into wild-type and rha-1(tm329) mutant 
animals.  (B) Lethality induced by glp-1(RNAi) by soaking wild-type and rha-1(tm329)
mutant animals. C) Lethality induced by feeding animals E.coli expressing par-6 dsRNA into 
wild-type and rha-1(tm329) mutant animals. Error bars represent standard deviations.
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Figure 5.5.- rha-1(tm329) is recessive.
 dsRNA targeting mom-2 was injected into wild-type, rha-1(tm329), animals heterozygous 
for rha-1 (rha-1(tm329)/+), and rde-2(ne221) control animals. Error bars represent standard 
deviations.
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Figure 5.6.- rha-1 is not required for RNAi of somatically expressed transcripts. 
dsRNA targeting two zygotically expressed transcripts (A) unc-102 and (B) unc-54 were 
injected into rha-1(tm329) and rde-4(ne301) control animals, and the percentage of 
uncoordinated animals was scored. (C) dsRNA  targeting GFP was injected alone or together 
with dsRNA targeting rha-1 or dcr-1 into an ELT-2::GFP strain.  Fluorescence in the 
progeny was scored.  dsRNA targeting unc-54 was used as a control.
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Figure 5.7. Him and revertant assay
 (A) L4 wild-type, rha-1 (tm329) and rde-2(ne221) control animals were placed at 25ºC for 
one generation and scored for the presence of males. (B) unc-22(r765::Tc4), mut-7(pk204); 
unc-22(r765::Tc4), and rha-1(tm329); unc-22(r765Tc4) animals were placed at 25ºC for two 
generations and numbers of wild-type revertants was scored.  Error bars represent standard 
deviations.
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Figure 5.8.- Transgeneic RHA-1::GFP shows nuclear enrichment. 
An integrated and rescuing RHA-1::GFP construct expressed in rha-1(tm329) animals shows 
both cytoplasmic and nuclear expression. (A) Vulva musculature (B) intestine (C) lateral 
muscle.  Arrows point to nuclear enrichment, with nucleolar exclusion.
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Figure 5.9.- siRNA bypass assay.  
23nt mom-2 siRNAs were injected into wild-type, rha-1(tm329) and various RNAi mutant 
backgrounds and percent embryonic lethality was scored.
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Figure 5.10.- rha-1(tm329) animals have germline defects. 
(A) wild-type and rha-1 males and hermaphrodites were mated in reciprocal experiments and 
percent cross progeny was scored.  (B) Wild-type and rha-1(tm329) animals were transferred 
daily and total brood size was scored at 20ºC and 25ºC.
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Figure 5.11.- Seam cell assays. 
(A) dsRNA targeting dcr-1, rha-1, and unc-54 (control) was injected into L4 animals of a 
strain carrying a GFP seam cell marker and numbers of seam cells was scored in the adult. 
Each bar represents one animal, for a total of 10 animals scored in each experiment (B) The 
alae were visualized by DIC microscopy in wild-type, rha-1(tm329) and dcr-1 (RNAi) 
animals.  Arrows point to defective alae in dcr-1(RNAi) animals. (C) dsRNA targeting dcr-1 
or rha-1 was injected into L4 animals of a strain carrying a GFP marker outlining the seam 
cells (AJM::GFP) and seam cell fusions was observed by epi-fluorescence.  Seam cells which 
fail to fuse form a rope like structure as seen in dcr-1(RNAi) animals. Arrow points to seam 
cells that have failed to fuse.  
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Figure 5.12.- rha-1(tm329) mutant animals are uniquely sensitive to par-2(RNAi).
  (A) rha-1(tm329) is sensitive to par-2(RNAi). dsRNAs corresponding to a disctinct region 
of the par-2 gene from that used in figure 12B and Table 2, was injected into wild-type and 
rha-1(tm329) mutant animals. Injection into rde-4(ne301) animals served as a control. (B)  
dsRNA targeting par-2 was injected into various RNAi mutant backgrounds, including rha-
1(tm329) and mut-14(pk204) both of which encode ATP-dependent DEAD Box helicases.  
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Table 5.2: Raw data for allele injections.  Each set of injections comprises one 
row, with the injected dsRNAs shown along the top, the genetic backgrounds 
injected on the left. The average percent lethality in resulting embryos is shown 
with number of repeat experiments in parenthesis. 
Avg % let (# of exp)
allele
nmy-2 
inj mom-2 inj ama-1 inj par-3 inj pos-1 inj par-2 inj
N2 wild-type 80.2 (3) 89.533 (15) 92.5 (2) 88 (2) 77 (2) 73.3(3)
rha-1(tm329)
15.66 
(3) 13.545  (11) 33 (2) 31.5 (2) 22 (3) 70.1 (5)
hpl-1(ok1060)
18.66 
(3) 4 (2) 44 (2) 18.5 (2) 80 (2)
hpl-1 (tm1624) 32.5 (2) 46.666 (3) 50 (2) 69 (2)
lin-13(ok838) 2.33 (3) 16 (4) 3 (2) 19 (2) 3 (2)
lin-13(n387) 87 (2) 99 (2)
lin-13(n770) 20.5 (2) 5 (1) 34 (2) 12.5 (2) 6 (2)
chd-3(eh4) 16 (3) 71 (3) 47.5 (2)
tam-1(cc567)
13.33 
(3) 9 (2) 44.5 (2) 88.5(2)
grt-1(sy272) 10 (2) 38 (1) 45 (2)
cec-1(ok1063) 44 (2) 32 (3) 35.5 (2) 98 (1)
lin-59(sa489) 44.33 (3)
lin-59 
(cxTi9220) 2 (2) 0 (2)
mys-1(tm1678) 52 (1) 22 (2)
lim-6(nr2073) 0 (2) 6 (1) 0 (2)
gap-2(tm748) 5 (2) 51.5 (2) 100 (1) 100 (1)
rnf-5(tm784) 43 (1) 29.5 (2) 93 (1) 95 (1)
hil-1(gk228) 82 (1) 45 (1) 22 (2) 77 (1)
lim-4(ky403) 17 (2) 74 (1)
gei-7(ok531) 37.5 (2) 71 (1) 20 (2)
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20ºC 25ºC
-tubulin::GFP 0/1200
(0%)
0/900
(0%)
mut-7(pk204);  -tubulin::GFP 0/898
(0%)
720/759
(95%)
rha-1(tm329); -
tubulin::GFP
0/948
(0%)
899/921
(98%)
TABLE 5.3: Loss of rha-1 can desilencea transgenes in the germline Number of total progeny
 scored for GFP re-expression after two generations at 20ºC and 25ºC are shown.
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Table 5.4: RHA-1 is required for fertility
     Percent Sterilitya
20ºC     25ºC
rha-1(tm329) 201/1054 (19%) 620/620 
(100%)
rha-1(tm329);RHA-1::GFP 655/931   (70%) 499/499 
(100%)
wild-type;RHA-1::GFP 588/705   (83%) 711/711 
(100%)
a Animals were scored for sterility as determined by cleared gonads after 3 
generations at 20ºC and 25ºC
